

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Seale

09/914,872

Welcome to STN International! Enter x:x

LOGINID:sssptau125rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in
WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names
added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26 Jul 21 Identification of STN records implemented
NEWS 27 Jul 21 Polymer class term count added to REGISTRY
NEWS 28 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
Right Truncation available
NEWS 29 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 30 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31 AUG 15 PATDPAFULL: one FREE connect hour, per account, in
September 2003
NEWS 32 AUG 15 PCTGEN: one FREE connect hour, per account, in
September 2003
NEWS 33 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in
September 2003
NEWS 34 AUG 15 TEMA: one FREE connect hour, per account, in
September 2003
NEWS 35 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 36 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 37 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation

NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:42:30 ON 16 SEP 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:42:39 ON 16 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 SEP 2003 HIGHEST RN 586329-53-5
DICTIONARY FILE UPDATES: 15 SEP 2003 HIGHEST RN 586329-53-5

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s eplerenone

L1 1 EPLERENONE

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 107724-20-9 REGISTRY
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,
.gamma.-lactone, methyl ester, (7.alpha.,11.alpha.,17.alpha.)- (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN Spiro[9,11-epoxy-9H-cyclopenta[a]phenanthrene-17(2H),2'(3'H)-furan],
pregn-4-ene-7,21-dicarboxylic acid deriv.

OTHER NAMES:

CN CGP 30083

CN **Eplerenone**

CN SC 66110

FS STEREOSEARCH


MF C24 H30 O6

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA,
CAPLUS, CASREACT, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
DRUGUPDATES, EMBASE, IPA, MEDLINE, PHAR, PROMT, SYNTHLINE, TOXCENTER,
USAN, USPAT2, USPATFULL

Absolute stereochemistry.



514/175
514/171
514/423

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

82 REFERENCES IN FILE CA (1937 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
85 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

6.30 6.51

FILE 'CAPLUS' ENTERED AT 11:43:07 ON 16 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Sep 2003 VOL 139 ISS 12

FILE LAST UPDATED: 15 Sep 2003 (20030915/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> e heart

E1	2	HEARSON/BI
E2	81	HEARST/BI
E3	277174	--> HEART/BI
E4	2	HEART004/BI
E5	1	HEART10001420/BI
E6	1	HEART10001490/BI
E7	1	HEART20000350/BI
E8	1	HEART20000990/BI
E9	1	HEART20003090/BI
E10	1	HEART20004110/BI
E11	1	HEART20004480/BI
E12	1	HEART20004920/BI

=> s e3

L2 277174 HEART/BI

=> s l1

L3 85 L1

=> s l2 and l3

L4 53 L2 AND L3

=> e failure

E1	1	FAILULRE/BI
E2	36	FAILUR/BI
E3	148245	--> FAILURE/BI
E4	1	FAILURE3/BI
E5	1	FAILURE4/BI
E6	2	FAILUREA/BI
E7	1	FAILUREAND/BI
E8	21	FAILED/BI
E9	2	FAILUREF/BI
E10	3	FAILUREFREE/BI
E11	1	FAILUREIN/BI
E12	1	FAILURELESS/BI

=> s e3

L5 148245 FAILURE/BI

=> s l4 and l5

L6 41 L4 AND L5

=> d l6 and captopril

'AND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

'CAPTOPRIL' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default)
 CAN ----- List of CA abstract numbers without answer numbers
 CBIB ----- AN, plus Compressed Bibliographic Data
 DALL ----- ALL, delimited (end of each field identified)
 DMAX ----- MAX, delimited for post-processing
 FAM ----- AN, PI and PRAI in table, plus Patent Family data
 FBIB ----- AN, BIB, plus Patent FAM
 IND ----- Indexing data
 IPC ----- International Patent Classifications
 MAX ----- ALL, plus Patent FAM, RE
 PATS ----- PI, SO
 SAM ----- CC, SX, TI, ST, IT
 SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
 SCAN must be entered on the same line as the DISPLAY,
 e.g., D SCAN or DISPLAY SCAN)
 STD ----- BIB, IPC, and NCL

 IABS ----- ABS, indented with text labels
 IALL ----- ALL, indented with text labels
 IBIB ----- BIB, indented with text labels
 IMAX ----- MAX, indented with text labels
 ISTD ----- STD, indented with text labels

 OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

 SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

 HIT ----- Fields containing hit terms
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
 ENTER DISPLAY FORMAT (BIB):bib

L6 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:678514 CAPLUS
 TI Methods of treating or preventing a cardiovascular condition using a
 cyclooxygenase-1 inhibitor
 IN Krul, Elaine S.
 PA USA

SO U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2003162824	A1	20030828	US 2002-292255	20021112
PRAI	US 2001-331346P	P	20011112		
	US 2001-338291P	P	20011113		

=> d his

(FILE 'HOME' ENTERED AT 11:42:30 ON 16 SEP 2003)

FILE 'REGISTRY' ENTERED AT 11:42:39 ON 16 SEP 2003
L1 1 S EPLERENONE

FILE 'CAPLUS' ENTERED AT 11:43:07 ON 16 SEP 2003
E HEART
L2 277174 S E3
L3 85 S L1
L4 53 S L2 AND L3
E FAILURE
L5 148245 S E3
L6 41 S L4 AND L5

=> e captopril

E1	1	CAPTOPRI/BI
E2	1	CAPTOPRIIL/BI
E3	6439 -->	CAPTOPRIL/BI
E4	2	CAPTOPRILATO/BI
E5	1	CAPTOPRILCYSTEINE/BI
E6	1	CAPTOPRILDECREASED/BI
E7	1	CAPTOPRILDISULFIDE/BI
E8	1	CAPTOPRILDURING/BI
E9	1	CAPTOPRILE/BI
E10	1	CAPTOPRILF3/BI
E11	1	CAPTOPRILIN/BI
E12	1	CAPTOPRILL/BI

=> s e3

L7 6439 CAPTOPRIL/BI

=> s l6 and l7

L8 5 L6 AND L7

=> d l8 1-5

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:678514 CAPLUS
TI Methods of treating or preventing a cardiovascular condition using a
cyclooxygenase-1 inhibitor
IN Krul, Elaine S.
PA USA
SO U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	US 2003162824	A1	20030828	US 2002-292255	20021112
PRAI	US 2001-331346P	P	20011112		
	US 2001-338291P	P	20011113		

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:319257 CAPLUS
 DN 138:343856
 TI Buccal sprays or capsules containing cardiovascular or renal drugs
 IN Dugger, Harry A.
 PA USA
 SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 537,118.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003077229	A1	20030424	US 2002-230075	20020829
	WO 9916417	A1	19990408	WO 1997-US17899	19971001
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	EP 1029536	A1	20000823	EP 2000-109347	19971001
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
	EP 1036561	A1	20000920	EP 2000-109357	19971001
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
PRAI	WO 1997-US17899	A2	19971001		
	US 2000-537118	A2	20000329		
	EP 1997-911621	A3	19971001		

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:755214 CAPLUS
 DN 137:263024
 TI Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
 IN Murugesan, Natesan; Tellev, John E.; Macor, Jhon E.; Gu, Zhengxiang
 PA USA
 SO U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S. Ser. No. 643,640, abandoned.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002143024	A1	20021003	US 2000-737201	20001214
PRAI	US 1998-91847P	P	19980706		
	US 1999-345392	B2	19990701		
	US 1999-464037	B2	19991215		
	US 2000-481197	B2	20000111		
	US 2000-513779	A2	20000225		
	US 2000-604322	A2	20000626		
	US 2000-643640	B2	20000822		
OS	MARPAT 137:263024				

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:628026 CAPLUS
 DN 133:227793
 TI Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
 IN Alexander, John C.; Roniker, Barbara; Desai, Subhash
 PA G.D. Searle & Co., USA
 SO PCT Int. Appl., 212 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000051642	A1	20000908	WO 2000-US5633	20000303
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1165136	A1	20020102	EP 2000-912174	20000303
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008781	A	20020702	BR 2000-8781	20000303
	JP 2002538172	T2	20021112	JP 2000-602308	20000303
PRAI	US 1999-122977P	P	19990305		
	WO 2000-US5633	W	20000303		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:335231 CAPLUS
 DN 132:352793
 TI Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
 IN Perez, Alfonso T.; Lachapelle, Richard J.; Roniker, Barbara; Asner, Debra J.; Alexander, John C.
 PA G.D. Searle & Co., USA
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027380	A2	20000518	WO 1999-US26206	19991105
	WO 2000027380	A3	20000824		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				

	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
BR 9915134	A	20010807	BR 1999-15134 19991105
EP 1126880	A2	20010829	EP 1999-960221 19991105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6410524	B1	20020625	US 1999-434685 19991105
JP 2002529405	T2	20020910	JP 2000-580609 19991105
NO 2001002229	A	20010703	NO 2001-2229 20010504
ZA 2001003632	A	20020506	ZA 2001-3632 20010504
US 2003040484	A1	20030227	US 2002-77134 20020215
PRAI US 1998-107398P	P	19981106	
US 1999-122977P	P	19990305	
US 1999-122978P	P	19990305	
US 1999-434685	A3	19991105	
WO 1999-US26206	W	19991105	

=> d his

(FILE 'HOME' ENTERED AT 11:42:30 ON 16 SEP 2003)

FILE 'REGISTRY' ENTERED AT 11:42:39 ON 16 SEP 2003
L1 1 S EPLERENONE

FILE 'CAPLUS' ENTERED AT 11:43:07 ON 16 SEP 2003
E HEART
L2 277174 S E3
L3 85 S L1
L4 53 S L2 AND L3
E FAILURE
L5 148245 S E3
L6 41 S L4 AND L5
E CAPTOPRIL
L7 6439 S E3
L8 5 S L6 AND L7

=> s 17 not 18
L9 6434 L7 NOT L8

=> s 16 not 18
L10 36 L6 NOT L8

=> d 110 15-36

L10 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:883649 CAPLUS
DN 139:127662
TI Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With **Heart Failure**
AU Suzuki, George; Morita, Hideaki; Mishima, Takayuki; Sharov, Victor G.; Todor, Anastassia; Tanhehco, Elaine J.; Rudolph, Amy E.; McMahon, Ellen G.; Goldstein, Sidney; Sabbah, Hani N.
CS Division of Cardiovascular Medicine, Departments of Medicine, Henry Ford Heart & Vascular Institute, Detroit, MI, 48202, USA
SO Circulation (2002), 106(23), 2967-2972
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:861225 CAPLUS
 DN 137:345479
 TI Eplerenone: The first selective aldosterone receptor antagonist for the treatment of hypertension
 AU Coleman, Craig I.; Reddy, Prabashni; Song, Jessica C.; White, C. Michael
 CS Hartford Hospital, Hartford, USA
 SO Formulary (2002), 37(10), 514, 517-522, 524
 CODEN: FORMF9; ISSN: 1082-801X
 PB Advanstar Communications, Inc.
 DT Journal; General Review
 LA English
 RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:821270 CAPLUS
 DN 137:304914
 TI Eplerenone - a novel selective aldosterone blocker
 AU Zillich, Alan J.; Carter, Barry L.
 CS Division of Clinical and Administrative Pharmacy and Department of Family Medicine, Colleges of Pharmacy and Medicine, University of Iowa, Iowa City, IA, USA
 SO Annals of Pharmacotherapy (2002), 36(10), 1567-1576
 CODEN: APHRER; ISSN: 1060-0280
 PB Harvey Whitney Books Co.
 DT Journal; General Review
 LA English
 RE.CNT 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:619761 CAPLUS
 DN 138:163269
 TI Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia
 AU Mihailidou, Anastasia S.; Mardini, Mahidi; Funder, John W.; Raison, Matthew
 CS Department of Cardiology, Royal North Shore Hospital, Sydney, 2065, Australia
 SO Hypertension (2002), 40(2), 124-129
 CODEN: HPRTDN; ISSN: 0194-911X
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:171665 CAPLUS
 DN 136:210586
 TI Use of an aldosterone receptor antagonist to improve cognitive function
 IN Fedde, Kenton N.; Perez, Alfonso T.; Tooley, Joseph F.
 PA Pharmacia Corporation, USA
 SO PCT Int. Appl., 177 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2002017895 A2 20020307 WO 2001-US26760 20010828
 WO 2002017895 A3 20030206
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2001085318 A5 20020313 AU 2001-85318 20010828
 US 2002111337 A1 20020815 US 2001-941206 20010828
 EP 1313485 A2 20030528 EP 2001-964471 20010828
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRAI US 2000-228738P P 20000828
 WO 2001-US26760 W 20010828

L10 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:107160 CAPLUS

DN 136:161366

TI Epoxy-steroidal aldosterone antagonist and calcium channel blocker
 combination therapy for treatment of congestive **heart**
failure and other cardiovascular disorders

IN Schuh, Joseph R.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 231 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002009761	A2	20020207	WO 2001-US23677	20010727
	WO 2002009761	A3	20030103		
	WO 2002009761	C2	20030710		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	US 2002042405	A1	20020411	US 2001-917425	20010727
	EP 1303305	A2	20030423	EP 2001-956001	20010727
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	US 2003055027	A1	20030320	US 2002-126134	20020419
PRAI	US 2000-221359P	P	20000727		
	US 2001-917425	B1	20010727		
	WO 2001-US23677	W	20010727		

L10 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:107159 CAPLUS

DN 136:172753

TI Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist
 combination therapy for treatment of congestive **heart**
failure

IN Alexander, John C.; Schuh, Joseph R.

PA Pharmacia Corporation, USA
SO PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002009760	A2	20020207	WO 2001-US23670	20010727
	WO 2002009760	A3	20030123		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002123485	A1	20020905	US 2001-917403	20010727
	EP 1303306	A2	20030423	EP 2001-957290	20010727
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-221365P	P	20000727		
	WO 2001-US23670	W	20010727		

L10 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:41643 CAPLUS
DN 136:210676
TI Eplerenone: A selective aldosterone receptor antagonist (SARA)
AU Delyani, John A.; Rocha, Ricardo; Cook, Chyung S.; Tolbert, Dwain S.; Levin, Stuart; Roniker, Barbara; Workman, Diane L.; Sing, Yuen-lung L.; Whelihan, Brian
CS Skokie, IL, 60077, USA
SO Cardiovascular Drug Reviews (2001), 19(3), 185-200
CODEN: CDREEA; ISSN: 0897-5957
PB Neva Press
DT Journal; General Review
LA English
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:923600 CAPLUS
DN 136:31688
TI Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects
IN Williams, Gordon H.; Funder, John W.; Garthwaite, Susan M.; Roniker, Barbara; Fedde, Kenton N.; Rocha, Ricardo
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 318 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001095893	A1	20011220	WO 2000-US31263	20001114
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,			

SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003125312 A1 20030703 US 2001-915784 20010726
 PRAI US 2000-211064P P 20000613
 US 2000-211250P P 20000613
 US 2000-211253P P 20000613
 US 2000-211264P P 20000613
 US 2000-211311P P 20000613
 US 2000-211340P P 20000613
 US 2000-211451P P 20000613
 US 2000-211459P P 20000613
 US 2000-221358P P 20000727
 US 2000-221364P P 20000727
 US 2000-233056P P 20000914
 US 2001-261352P P 20010112
 US 2001-261497P P 20010112

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:923599 CAPLUS

DN 136:31687

TI Use of an aldosterone antagonist, specifically a spiro lactone-type
 steroidal compound, for the treatment or prophylaxis of
 aldosterone-mediated pathogenic effects

IN Williams, Gordon H.; Funder, John W.; Garthwaite, Susan M.; Roniker,
 Barbara; Fedde, Kenton N.; Rocha, Ricardo

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 329 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001095892	A1	20011220	WO 2000-US31155	20001114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1289507	A1	20030312	EP 2000-978588	20001114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003125312	A1	20030703	US 2001-915784	20010726
PRAI	US 2000-211064P	P	20000613		
	US 2000-211250P	P	20000613		
	US 2000-211253P	P	20000613		
	US 2000-211264P	P	20000613		
	US 2000-211311P	P	20000613		
	US 2000-211340P	P	20000613		
	US 2000-211451P	P	20000613		
	US 2000-211459P	P	20000613		
	US 2000-221358P	P	20000727		
	US 2000-221364P	P	20000727		

US 2000-233056P P 20000914
WO 2000-US31155 W 20001114
US 2001-261352P P 20010112
US 2001-261497P P 20010112

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:620013 CAPLUS
DN 136:79474
TI The EPHESUS trial: Eplerenone in patients with **heart failure** due to systolic dysfunction complicating acute myocardial infarction.
AU Pitt, Bertram; Williams, Gordon; Remme, Willem; Martinez, Felipe; Lopez-Sendon, Jose; Zannad, Faiez; Neaton, James; Roniker, Barbara; Hurley, Steve; Burns, Dan; Bittman, Richard; Kleiman, Jay
CS Boston, USA
SO Cardiovascular Drugs and Therapy (2001), 15(1), 79-87
CODEN: CDTHET; ISSN: 0920-3206
PB Kluwer Academic Publishers
DT Journal
LA English

RE.CNT 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:620004 CAPLUS
DN 135:352191
TI New treasures from old? EPHESUS
AU Pfeffer, Marc A.
CS Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 02115, USA
SO Cardiovascular Drugs and Therapy (2001), 15(1), 11-13
CODEN: CDTHET; ISSN: 0920-3206
PB Kluwer Academic Publishers
DT Journal; General Review
LA English

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:434870 CAPLUS
DN 135:51047
TI Nanoparticulate eplerenone compositions
IN Thosar, Shilpa S.; Gokhale, Rajeev D.; Tolbert, Dwain S.; Desai, Subhash
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 2001041770	A2	20010614	WO 2000-US30179	20001204
	WO 2001041770	A3	20011122		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,			

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1175220 A2 20020130 EP 2000-980277 20001204
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 US 2002006919 A1 20020117 US 2000-732246 20001207
 PRAI US 1999-169658P P 19991208
 US 2000-208981P P 20000602
 WO 2000-US30179 W 20001204

L10 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:369262 CAPLUS
 DN 135:235708
 TI Eplerenone (GD Searle & Co)
 AU Martin, Jennifer; Krum, Henry
 CS Alfred Hospital, Monash University, Victoria, 3181, Australia
 SO Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2001), 2(4),
 521-524
 CODEN: COIDAZ
 PB PharmaPress Ltd.
 DT Journal; General Review
 LA English
 RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:262624 CAPLUS
 DN 135:70465
 TI Recent studies with eplerenone, a novel selective aldosterone receptor
 antagonist
 AU McMahon, Ellen G.
 CS Pharmacia Corporation, St Louis, MO, 63167, USA
 SO Current Opinion in Pharmacology (2001), 1(2), 190-196
 CODEN: COPUBK; ISSN: 1471-4892
 PB Elsevier Science Ltd.
 DT Journal; General Review
 LA English
 RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:74077 CAPLUS
 DN 134:126077
 TI Pathophysiology of aldosterone and its antagonists
 AU Struthers, A. D.
 CS Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital
 and Medical School, DD1 9SY, Dundee, UK
 SO Fundamental & Clinical Pharmacology (2000), 14(6), 549-552
 CODEN: FCPHEZ; ISSN: 0767-3981
 PB Editions Scientifiques et Medicales Elsevier
 DT Journal; General Review
 LA English
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:404555 CAPLUS
 DN 133:144998
 TI Eplerenone, a new mineralocorticoid antagonist: in vitro and in vivo
 studies
 AU Funder, John W.
 CS Baker Medical Research Institute, Melbourne, 8008, Australia

SO Current Opinion in Endocrinology & Diabetes (2000), 7(3), 138-142
 CODEN: CENDES; ISSN: 1068-3097
 PB Lippincott Williams & Wilkins
 DT Journal; General Review
 LA English
 RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:307849 CAPLUS
 DN 133:68245
 TI Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology
 AU Delyani, John A.
 CS Searle Research and Development, St. Louis, MO, USA
 SO Kidney International (2000), 57(4), 1408-1411
 CODEN: KDYIA5; ISSN: 0085-2538
 PB Blackwell Science, Inc.
 DT Journal; General Review
 LA English
 RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:259979 CAPLUS
 DN 132:288794
 TI Sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance
 IN Anker, Stefan Dietmar; Coats, Andrew Justin Stewart
 PA Imperial College Innovations Limited, UK
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021509	A2	20000420	WO 1999-GB3302	19991015
	WO 2000021509	A3	20001109		
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1121111	A2	20010808	EP 1999-947762	19991015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002527378	T2	20020827	JP 2000-575485	19991015
PRAI	GB 1998-22458	A	19981015		
	GB 1998-22459	A	19981015		
	GB 1999-17181	A	19990723		
	WO 1999-GB3302	W	19991015		

L10 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:485717 CAPLUS
 DN 132:78735
 TI Eplerenone. Antihypertensive treatment of **heart failure** aldosterone antagonist
 AU Rabasseda, X.; Silvestre, J.; Castaner, J.
 CS Prous Science, Barcelona, 08080, Spain
 SO Drugs of the Future (1999), 24(5), 488-501
 CODEN: DRFUD4; ISSN: 0377-8282
 PB Prous Science

DT Journal; General Review
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:331138 CAPLUS
DN 129:63048
TI Anti-aldosterone therapy in the treatment of **heart failure**: new thoughts on an old hormone
AU Delyani, John A.
CS Searle Research and Development, St. Louis, MO, 63167, USA
SO Expert Opinion on Investigational Drugs (1998), 7(5), 753-759
CODEN: EOIDER; ISSN: 1354-3784
PB Ashley Publications
DT Journal; General Review
LA English

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:168547 CAPLUS
DN 126:152803
TI Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**
IN Alexander, John C.; Schuh, Joseph R.; Gorczynski, Richard J.
PA G.D. Searle & Co., USA; Alexander, John C.; Schuh, Joseph R.; Gorczynski, Richard J.
SO PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640257	A1	19961219	WO 1996-US9335	19960605
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	CA 2224079	AA	19961219	CA 1996-2224079	19960605
	AU 9661577	A1	19961230	AU 1996-61577	19960605
	AU 725689	B2	20001019		
	EP 831910	A1	19980401	EP 1996-919170	19960605
	EP 831910	B1	20011121		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1192697	A	19980909	CN 1996-196155	19960605
	BR 9609066	A	19990126	BR 1996-9066	19960605
	JP 11507627	T2	19990706	JP 1996-501678	19960605
	NZ 310730	A	20010126	NZ 1996-310730	19960605
	RU 2166330	C2	20010510	RU 1998-100250	19960605
	IL 122242	A1	20010724	IL 1996-122242	19960605
	AT 209047	E	20011215	AT 1996-919170	19960605
	ES 2167571	T3	20020516	ES 1996-919170	19960605
	RO 118046	B1	20030130	RO 1997-2272	19960605
	PL 185150	B1	20030331	PL 1996-324001	19960605
	NO 9705741	A	19980129	NO 1997-5741	19971205
PRAI	US 1995-486456	A	19950607		
	WO 1996-US9335	W	19960605		

OS MARPAT 126:152803

=> d 110 36 all

L10 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:168547 CAPLUS
DN 126:152803
TI Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist
combination therapy for treatment of cardiovascular disorders, including
congestive **heart failure**
IN Alexander, John C.; Schuh, Joseph R.; Gorczynski, Richard J.
PA G.D. Searle & Co., USA; Alexander, John C.; Schuh, Joseph R.; Gorczynski,
Richard J.
SO PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K045-06
ICS A61K031-585
CC 1-8 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9640257	A1	19961219	WO 1996-US9335	19960605
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA			
	CA 2224079	AA	19961219	CA 1996-2224079	19960605
	AU 9661577	A1	19961230	AU 1996-61577	19960605
	AU 725689	B2	20001019		
	EP 831910	A1	19980401	EP 1996-919170	19960605
	EP 831910	B1	20011121		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	CN 1192697	A	19980909	CN 1996-196155	19960605
	BR 9609066	A	19990126	BR 1996-9066	19960605
	JP 11507627	T2	19990706	JP 1996-501678	19960605
	NZ 310730	A	20010126	NZ 1996-310730	19960605
	RU 2166330	C2	20010510	RU 1998-100250	19960605
	IL 122242	A1	20010724	IL 1996-122242	19960605
	AT 209047	E	20011215	AT 1996-919170	19960605
	ES 2167571	T3	20020516	ES 1996-919170	19960605
	RO 118046	B1	20030130	RO 1997-2272	19960605
	PL 185150	B1	20030331	PL 1996-324001	19960605
	NO 9705741	A	19980129	NO 1997-5741	19971205
PRAI	US 1995-486456	A	19950607		
	WO 1996-US9335	W	19960605		

OS MARPAT 126:152803

AB A combination therapy comprising a therapeutically-effective amt. of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amt. of an angiotensin II receptor antagonist is described for treatment of circulatory disorders, including cardiovascular disorders, e.g. hypertension and congestive **heart failure**. Preferred angiotensin II receptor antagonists are those compds. having high potency and bioavailability and which are characterized in having an imidazole or triazole moiety attached to a biphenylmethyl or pyridinyl/phenylmethyl moiety. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by

the presence of 9.alpha.,11.alpha.-substituted epoxy moiety. A preferred combination therapy includes the angiotensin II receptor antagonist 5-[2-[5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole and the aldosterone receptor antagonist epoxymexrenone.

ST angiotensin II antagonist combination cardiovascular disorder;
epoxysteroid aldosterone antagonist combination cardiovascular disorder;
hypertension congestive **heart failure** therapeutic
combination; cardiovascular disorder therapeutic combination;
epoxymexrenone ATII antagonist combination cardiovascular disorder

IT Angiotensin receptor antagonists
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(angiotensin II; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT Antihypertensives
Cardiovascular agents
Drug delivery systems
(epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT Mineralocorticoid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT Steroids, biological studies
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(epoxy; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT **Heart, disease**
(**failure**; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 141871-61-6, A 81282
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(A 81282; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 122088-76-0, CGP 38560A
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(CGP 38560A; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 135689-23-5, CGP 48369
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(CGP 48369; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 114798-36-6, DuP 167

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (DuP 167; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 153049-46-8, EXP 063
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (EXP 063; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 136042-19-8, FK 739
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (FK 739; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 138620-04-9, ICI-D 6888
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (ICI-D 6888; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 133240-72-9, L 158978
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (L 158978; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 154512-46-6, L 162441
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (L 162441; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 148564-45-8, LR-B 057
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (LR-B 057; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 154200-12-1, RWJ 46458
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (RWJ 46458; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 149285-55-2, WAY 126227
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (WAY 126227; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 151406-07-4, YM 358
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (YM 358; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 34273-10-4, Saralasin 39698-78-7, Saralasin acetate 88874-29-7, Sarmesin 95508-61-5, Isoteolin 95716-76-0 95716-78-2 95716-95-3 95716-96-4 95716-97-5 95716-98-6 95716-99-7 95717-01-4 95717-02-5 105186-68-3, KRI-1177 **107724-20-9** 114773-44-3, EXP-6803 114785-12-5, PD-123177 114798-27-5, EXP-7711 114798-32-2, EXP-9270 118393-93-4, S-8307 119256-78-9, S-8308 121280-51-1, EXP-6155 124750-92-1, EXP-3174 124750-95-4, DuP-532 124750-99-8, Losartan potassium 130663-39-7, PD-123319 133040-01-4, Eprosartan 133051-66-8 133051-78-2 133085-33-3, BIBS39 133240-46-7, L-158809 133690-62-7 133732-33-9 135015-84-8, ZD-8731 135070-05-2, E-4177 136284-47-4, CV-11194 137862-53-4, Valsartan 138402-11-6, Irbesartan 139476-18-9 139476-19-0 139476-20-3 139476-21-4 139476-22-5 139476-23-6 139476-24-7 139476-25-8 139476-26-9 139476-27-0 139476-28-1 139476-29-2 139476-30-5 139476-31-6 139476-32-7 139476-33-8 139476-34-9 139476-35-0 139476-37-2 139476-38-3 139476-40-7 139476-41-8 139476-42-9 139476-43-0 139481-59-7, Candesartan 139501-60-3 139501-61-4 139501-62-5 139958-16-0, ME-3221 139964-19-5, DMP-811 140120-40-7 140120-41-8 140120-42-9 140120-43-0 140120-44-1 140120-45-2 140120-46-3 140120-47-4 140120-48-5 140120-49-6 140120-50-9 140120-51-0 140120-52-1 140120-53-2 140120-54-3 140120-55-4 140120-56-5 140120-57-6 140120-58-7 140120-59-8 140120-60-1 140120-61-2 140120-62-3 140120-63-4 140120-64-5 140120-65-6 140120-66-7 140120-67-8 140120-68-9 140120-70-3 140120-71-4 140120-72-5 140120-73-6 140120-75-8 140120-76-9 140120-77-0 140120-78-1 140120-79-2 140120-80-5 140120-81-6 140120-82-7 140120-84-9 140120-86-1 140120-88-3 140120-89-4 140120-91-8 140120-93-0 140120-94-1 140120-96-3 140120-97-4 140120-98-5 140120-99-6 140121-00-2 140121-01-3 140121-02-4 140121-03-5 140121-04-6 140121-05-7 140121-06-8 140121-07-9 140121-08-0 140121-09-1 140121-10-4 140121-11-5 140121-14-8 140121-15-9 140121-16-0 140121-17-1 140121-18-2 140126-38-1 140157-30-8 140157-31-9 140157-32-0 140199-14-0 140199-15-1 140199-16-2 140199-17-3 140199-18-4 140199-19-5 140199-20-8 140199-21-9 140199-22-0 140199-23-1 140199-24-2 140199-26-4 140199-27-5 140199-48-0 140199-49-1 141386-89-2 141386-95-0 141387-00-0 141387-02-2 141387-42-0 141887-34-5, A-81988 142023-57-2, BIBS-222 142410-81-9 142410-86-4 142410-88-6 142410-89-7 142999-90-4, BMS-180560 143494-72-8, ICI-D8731 143573-49-3 143573-50-6 143573-55-1 143573-56-2 143573-57-3 143573-58-4 144062-54-4 144062-55-5 144062-56-6 144062-57-7 144062-58-8 144062-59-9 144062-60-2 144062-61-3 144701-48-4, Telmisartan 144873-19-8 144873-21-2 144873-25-6 144873-32-5 145004-82-6, L-161177 145040-37-5, Candesartan cilexetil 145061-98-9 145062-04-0 145062-14-2 145160-47-0 145160-48-1 145160-49-2 145160-50-5 145160-51-6 145160-52-7 145160-53-8 145160-54-9 145160-55-0 145160-56-1 145160-57-2 145160-58-3 145160-59-4 145160-60-7 145160-61-8 145160-62-9 145160-63-0 145160-64-1 145160-65-2 145160-66-3 145160-67-4 145160-68-5 145160-69-6 145160-70-9 145160-71-0 145160-72-1 145160-73-2 145160-74-3 145160-75-4 145160-76-5 145160-77-6 145160-78-7 145160-79-8 145160-80-1 145160-81-2 145160-82-3 145160-83-4 145160-84-5 145160-85-6 145160-86-7 145160-87-8

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 145160-88-9 145160-89-0 145216-03-1 145216-23-5 145216-43-9
145216-51-9 145216-54-2 145216-57-5 145216-83-7 145217-23-8
145217-63-6 145218-03-7 145543-03-9, RG-13647 145733-36-4,
Tasosartan 145781-32-4, Zolasartan 146623-69-0, Sapisartan
146709-78-6, ZD-7155 146948-75-6, L 162234 148504-51-2, UP-269-6
148564-47-0, LR-B/081 149586-24-3, YM 31472 149810-30-0 149968-26-3
150438-02-1, CI-996 150484-27-8, L-159689 150802-50-9, KW 3433
152134-03-7, U-97018 153072-63-0, BMS-184698 153235-15-5, HR-720
153465-66-8, GA 0056 (pharmaceutical) 153804-05-8, KT3-671
154668-27-6, LY-301875 155617-69-9 155617-70-2 155617-71-3
155617-72-4 155961-06-1 155961-08-3 155961-10-7 155961-12-9
157263-00-8, L-159282 158776-83-1 158776-84-2 160936-33-4, SL 910102
165113-01-9 165113-02-0 165113-03-1 165113-04-2 165113-05-3
165113-06-4 165113-07-5 165113-08-6 165113-09-7 165113-14-4
169181-38-8, XR-510 169281-98-5, L-163017 172262-72-5 172345-25-4,
RWJ-38970 173661-98-8 173661-99-9 173662-00-5 173662-01-6
173662-02-7 173662-03-8 173662-04-9 173662-05-0 173662-06-1
173662-07-2 173662-08-3 173662-09-4 173662-10-7 173662-11-8
173662-12-9 173662-13-0 173662-14-1 173662-15-2 173662-16-3
173662-17-4 173662-18-5 173662-19-6 173662-20-9 173662-21-0
173662-22-1 173662-23-2 173662-24-3 173662-25-4 173662-26-5
173662-27-6 173662-28-7 186453-50-9 186453-64-5 186453-72-5
186453-73-6 186453-74-7 186453-75-8 186453-76-9 186453-77-0
186453-78-1 186453-79-2 186453-80-5 186453-81-6 186453-82-7
186453-83-8 186453-84-9 186453-85-0 186453-86-1 186453-87-2
186453-88-3 186453-89-4 186453-90-7 186453-91-8 186453-92-9
186453-93-0 186537-37-1, L 162154 186537-38-2, L 159874 186615-80-5,
BIBR 363 186615-82-7, CGP 49870 186615-83-8, CGP 63170 186615-84-9,
DA 2079 186615-85-0, DE 3489 186615-88-3, EMD 66397 186615-89-4, EMD
73495 186615-91-8, EXP 929 186615-99-6, ICI-D 7155 186616-01-3, L
163007 186616-03-5, LR-B 087 186616-04-6, LY 235656 186616-05-7, LY
285434 186616-06-8, LY 302289 186616-07-9, LY 315995 186616-10-4, PD
150304 186616-15-9, U 96849 186616-16-0, UP 275-22 186616-18-2, WK
1360 186616-19-3, WK 1492.2K 186616-20-6, X 6803 186616-21-7, XH 148
186817-55-0
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 52-39-1, Aldosterone 11128-99-7, Angiotensin II
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

=> d 110 35 all

L10 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:331138 CAPLUS
DN 129:63048
TI Anti-aldosterone therapy in the treatment of **heart failure**: new thoughts on an old hormone
AU Delyani, John A.
CS Searle Research and Development, St. Louis, MO, 63167, USA
SO Expert Opinion on Investigational Drugs (1998), 7(5), 753-759
CODEN: EOIDER; ISSN: 1354-3784

PB Ashley Publications
 DT Journal; General Review
 LA English
 CC 2-0 (Mammalian Hormones)
 AB A review, with 53 refs. Activation of the renin-angiotensin-aldosterone system (RAAS) is a prominent feature of left ventricular dysfunction and plays an important role in the progression of chronic **heart failure**. Clin. and animal studies investigating agents that interrupt this hormonal system have focused primarily on the proximal constituents of the RAAS, namely angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, and have largely neglected the possible pathol. consequences of another hormone in the system, aldosterone. Clin. evidence indicates that aldosterone plays an important role in chronic **heart failure**, even when other RAAS inhibiting agents are employed. Moreover, animal studies have indicated that aldosterone, in addn. to important renal effects, has direct cardiac and vascular effects. These data suggest that an anti-aldosterone therapeutic may provide important protection in chronic **heart failure**. Currently, only one therapeutic is available, spironolactone (Aldactone), and recent clin. studies support the contention that the addn. of spironolactone to std. **heart failure** therapy provides addnl. benefit. A highly selective aldosterone receptor antagonist, eplerenone, is currently in clin. development. Data from this new agent should provide important evidence supporting the benefit of anti-aldosterone therapy in chronic **heart failure**, which may encourage physicians to include an anti-aldosterone agent in the armamentarium of therapeutics currently used to combat chronic **heart failure**.

ST review spironolactone eplerenone aldosterone **heart failure**

IT Mineralocorticoid receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (antagonists; anti-aldosterone therapy in treatment of **heart failure** in animals and humans)

IT **Heart**, disease
 (failure, chronic; anti-aldosterone therapy in treatment of **heart failure** in animals and humans)

IT 52-01-7, Aldactone 107724-20-9, Eplerenone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-aldosterone therapy in treatment of **heart failure** in animals and humans)

IT 52-39-1, Aldosterone
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (anti-aldosterone therapy in treatment of **heart failure** in animals and humans)

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anderson, N; Endocrinology 1976, V98, P676 CAPLUS
- (2) Araki, T; Jpn Circ J 1995, V59, P213 CAPLUS
- (3) Arora, R; Life Sci 1962, V5, P215 MEDLINE
- (4) Barr, C; Am J Cardiol 1995, V76, P1259 CAPLUS
- (5) Bayliss, J; Br Heart J 1987, V57, P17 MEDLINE
- (6) Brilla, C; Cardiovasc Res 1992, V26, P671 CAPLUS
- (7) Brilla, C; J Mol Cell Cardiol 1994, V26, P809 CAPLUS
- (8) Chien, Y; J Pharm Sci 1976, V65, P1337 CAPLUS
- (9) Cohn, J; New Engl J Med 1991, V325, P303 MEDLINE
- (10) de Gasparo, M; J Pharmacol Exp Ther 1987, V240, P650 CAPLUS
- (11) Delyani, J; Am J Hypertens In Press

- (12) Denicola, A; Horm Metab Res 1981, V13, P103 CAPLUS
- (13) Dyckner, T; Am J Cardiol 1990, V65, P44
- (14) Dzau, V; New Engl J Med 1984, V310, P347 MEDLINE
- (15) Erbler, H; Eur J Clin Pharmacol 1976, V9, P253 MEDLINE
- (16) Friedrich, G; Am J Hypertens In Press
- (17) Fullerton, M; Cardiovasc Res 1994, V28, P1863 MEDLINE
- (18) Funder, J; Ann Rev Physiol 1993, V55, P115 CAPLUS
- (19) Funder, J; J Steroid Biochem 1972, V3, P209 CAPLUS
- (20) Hensen, J; Am J Nephrol 1991, V11, P441 MEDLINE
- (21) Hensen, J; Am J Nephrol 1991, V11, P441 MEDLINE
- (22) Hofman, L; J Pharm Sci 1974, V63, P1248
- (23) Kagawa, C; Science 1957, V126, P1015 CAPLUS
- (24) Karim, A; Clin Pharmacol Ther 1976, V19, P158 CAPLUS
- (25) Karim, A; Clin Pharmacol Ther 1976, V19, P177 CAPLUS
- (26) Karim, A; J Pharm Sci 1971, V60, P708 CAPLUS
- (27) Lombes, M; Circ Res 1992, V71, P503 CAPLUS
- (28) Mikami, H; Am J Hypertens 1988, V1, P4s CAPLUS
- (29) Moura, A; Hypertension 1984, V6, P425 CAPLUS
- (30) Pearce, P; Clin Exp Pharmacol Physiol 1987, V14, P859 CAPLUS
- (31) Peltola, P; Ann Med Exp Biol Fenn 1970, V48, P122 CAPLUS
- (32) Sadee, W; Eur J Clin Pharmacol 1974, V7, P195 CAPLUS
- (33) Sadee, W; J Pharm Sci 1972, V61, P1129 CAPLUS
- (34) Sadee, W; J Pharm Sci 1972, V61, P1132 CAPLUS
- (35) Sadee, W; J Pharmacol Exp Ther 1973, V185, P686 CAPLUS
- (36) Sadee, W; Naunyn Schmiedeberg's Arch Pharmacol 1974, V283, P303 CAPLUS
- (37) Saito, Y; Endocrinology 1991, V129, P2361
- (38) Schohn, D; Am J Cardiol 1990, V65, P4
- (39) Sheehan, J; Magnestum 1984, V3, P301 MEDLINE
- (40) Siscovick, D; New Engl J Med 1994, V330, P1852 MEDLINE
- (41) Solvd Investigators; New Engl J Med 1991, V295, P293
- (42) Struthers, A; J Card Fatl 1996, V2, P47 MEDLINE
- (43) Struthers, A; J Hum Hypertens 1995, V9, P443 MEDLINE
- (44) Taddei, S; Hypertension 1993, V21, P929 MEDLINE
- (45) The Consensus Trial Study; New Engl J Med 1987, V55, P3
- (46) The Rales Investigators; Am J Cardiol 1996, V78, P902
- (47) Weber, K; Postgrad Med 1993, V93, P203 MEDLINE
- (48) Wehling, M; Biochem Biophys Res Commun 1989, V164, P961 CAPLUS
- (49) Wehling, M; Biochem Biophys Res Commun 1991, V181, P1306 CAPLUS
- (50) Young, M; Am J Physiol 1995, V269, PE657 CAPLUS
- (51) Young, M; Am J Physiol 1996, V271, PE883 CAPLUS
- (52) Yusef, S; Circulation 1997, V96, P1452
- (53) Zannad, F; Eur Heart J 1995, V16, P98 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 11:42:30 ON 16 SEP 2003)

FILE 'REGISTRY' ENTERED AT 11:42:39 ON 16 SEP 2003

L1 1 S EPLERENONE

FILE 'CAPLUS' ENTERED AT 11:43:07 ON 16 SEP 2003

E HEART

L2 277174 S E3

L3 85 S L1

L4 53 S L2 AND L3

E FAILURE

L5 148245 S E3

L6 41 S L4 AND L5

E CAPTOPRIL

L7 6439 S E3

L8 5 S L6 AND L7

L9 6434 S L7 NOT L8
L10 36 S L6 NOT L8

=> e e ramipril

E1 3 DZZZ/BI
E2 1715148 E/BI
E3 0 --> E RAMIPRIL/BI
E4 8715 E0/BI
E5 82 E00/BI
E6 3 E000/BI
E7 1 E00011/BI
E8 1 E00052/BI
E9 10 E001/BI
E10 1 E00102/BI
E11 1 E00124/BI
E12 1 E00132/BI

=> e ramipril

E1 1 RAMIPRESA/BI
E2 1 RAMIPRESSA/BI
E3 852 --> RAMIPRIL/BI
E4 234 RAMIPRILAT/BI
E5 10 RAMIPRILATE/BI
E6 3 RAMIR/BI
E7 1 RAMIRAKKUSU/BI
E8 1 RAMIRES/BI
E9 2 RAMIRESUTA/BI
E10 2 RAMIREX/BI
E11 140 RAMIREZ/BI
E12 2 RAMIREZELLA/BI

=> s e3

L11 852 RAMIPRIL/BI

=> s l7 and l2

L12 1438 L7 AND L2

=> s l12 and l5

L13 435 L12 AND L5

=> d l13 400-435

L13 ANSWER 400 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1988:400815 CAPLUS

DN 109:815

TI Angiotensin-converting enzyme inhibitors useful in prolonging survival of
mammalians with congestive **heart failure**

IN Sweet, Charles S.

PA Merck and Co., Inc., USA

SO Eur. Pat. Appl., 4 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	EP 241201	A2	19871014	EP 1987-302769	19870331
	EP 241201	A3	19900523		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
	AU 8771103	A1	19871008	AU 1987-71103	19870406
	DK 8701740	A	19871008	DK 1987-1740	19870406
	JP 62242626	A2	19871023	JP 1987-83938	19870407

CA 1288351 A1 19910903 CA 1987-534041 19870407
PRAI US 1986-848528 19860407

L13 ANSWER 401 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1988:142873 CAPLUS
DN 108:142873
TI Arrhythmias during concurrent therapy with **captopril** and
frusemide
AU Daniels, Andre R.
CS Thames Hosp., Thames, N. Z.
SO New Zealand Medical Journal (1987), 100(835), 695
CODEN: NZMJAX; ISSN: 0028-8446
DT Journal
LA English

L13 ANSWER 402 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1988:87815 CAPLUS
DN 108:87815
TI Regional blood flow and hemodynamics in the rabbit with adriamycin
cardiomyopathy: effects of isosorbide dinitrate, dobutamine and
captopril
AU Wanless, Richard B.; Anand, Inder S.; Gurden, Jane; Harris, Peter;
Poole-Wilson, Philip A.
CS Cardiothorac. Inst., Natl. Heart Hosp., London, W1N 2DX, UK
SO Journal of Pharmacology and Experimental Therapeutics (1987), 243(3),
1101-6
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L13 ANSWER 403 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1988:49010 CAPLUS
DN 108:49010
TI **Captopril** inhibits the hydroosmotic effect of ADH in the
cortical collecting tubule
AU Rouse, Diane; Dalmeida, William; Williamson, Frank C.; Suki, Wadi N.
CS Dep. Med., Baylor Coll. Med., Houston, TX, USA
SO Kidney International (1987), 32(6), 845-50
CODEN: KDYIA5; ISSN: 0085-2538
DT Journal
LA English

L13 ANSWER 404 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:628815 CAPLUS
DN 107:228815
TI Effect of vasodilators on regional blood flow in a rat model of myocardial
infarction and **failure**
AU Drexler, H.
CS Med. Klin., Univ. Freiburg/Br., Freiburg/Br., Fed. Rep. Ger.
SO Fortschritte der Medizin (1987), 105(24), 464-6
CODEN: FMDZAR; ISSN: 0015-8178
DT Journal
LA German

L13 ANSWER 405 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:590705 CAPLUS
DN 107:190705
TI Central and regional vascular effects of milrinone in experimental
heart failure: comparison with **captopril** and
dobutamine
AU Drexler, H.; Faude, F.; Winterer, H.; Wollschlaeger, H.; Freudenberg, N.;
Just, H.

CS Med. Klin. III, Univ. Freiburg, Freiburg, 7800, Fed. Rep. Ger.
 SO Zeitschrift fuer Kardiologie (1987), 76(8), 507-13
 CODEN: ZKRDX; ISSN: 0300-5860
 DT Journal
 LA German

L13 ANSWER 406 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1987:526731 CAPLUS
 DN 107:126731
 TI Hemodynamic benefits and prolonged survival with long-term
captopril therapy in rats with myocardial infarction and
heart failure
 AU Pfeffer, Janice M.; Pfeffer, Marc A.; Braunwald, Eugene
 CS Dep. Med., Brigham and Women's Hosp., Boston, MA, 02115, USA
 SO Circulation, Supplement (1987), 75(1), I-149-I-155
 CODEN: CISUAQ; ISSN: 0069-4193
 DT Journal
 LA English

L13 ANSWER 407 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1987:451690 CAPLUS
 DN 107:51690
 TI Hemodynamic effects of **captopril** in acute left ventricular
failure complicating myocardial infarction
 AU McAlpine, Howard M.; Morton, James J.; Leckie, Brenda; Dargie, Henry J.
 CS Dep. Cardiol., West. Infirm., Glasgow, G11 6NT, UK
 SO Journal of Cardiovascular Pharmacology (1987), 9(Suppl. 2), S25-S30
 CODEN: JCPCDT; ISSN: 0160-2446
 DT Journal
 LA English

L13 ANSWER 408 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1987:432864 CAPLUS
 DN 107:32864
 TI Acute hemodynamic and neuroendocrine effects of dopexamine, a new
 vasodilator for the treatment of **heart failure**:
 comparison with dobutamine, **captopril**, and nitrate
 AU Bayliss, John; Thomas, Louise; Poole-Wilson, Philip
 CS Natl. Heart Hosp., London, UK
 SO Journal of Cardiovascular Pharmacology (1987), 9(5), 551-4
 CODEN: JCPCDT; ISSN: 0160-2446
 DT Journal
 LA English

L13 ANSWER 409 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1987:400588 CAPLUS
 DN 107:588
 TI Acute regional vascular effects of intravenous **captopril** in a
 rat model of myocardial infarction and **failure**
 AU Drexler, Helmut; Depenbusch, Joseph W.; Truog, Arnold G.; Zelis, Robert;
 Flaim, Stephen F.
 CS Coll. Med., Pennsylvania State Univ., Hershey, PA, USA
 SO Journal of Pharmacology and Experimental Therapeutics (1987), 241(1),
 13-19
 CODEN: JPETAB; ISSN: 0022-3565
 DT Journal
 LA English

L13 ANSWER 410 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1987:33100 CAPLUS
 DN 106:33100
 TI 5-Substituted-6-aminopyrimidines, their preparation and uses as

cardiotonic agents for increasing cardiac contractility
 IN Bagli, Jehan F.; Peseckis, Steven M.
 PA American Home Products Corp., USA
 SO U.S., 11 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4617393	A	19861014	US 1985-757214	19850719
	ZA 8604888	A	19880224	ZA 1986-4888	19860701
	AU 8659481	A1	19870122	AU 1986-59481	19860702
	EP 210025	A2	19870128	EP 1986-305331	19860711
	EP 210025	A3	19871021		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	HU 42455	A2	19870728	HU 1986-2887	19860711
	HU 195786	B	19880728		
	DK 8603352	A	19870120	DK 1986-3352	19860715
	JP 62022771	A2	19870130	JP 1986-167741	19860715
	CA 1287631	A1	19910813	CA 1986-513792	19860715
	ES 2000125	A6	19871216	ES 1986-383	19860718
PRAI	US 1985-757214		19850719		
OS	CASREACT 106:33100				

L13 ANSWER 411 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1986:583219 CAPLUS
 DN 105:183219
 TI What have we learned about inhibitors of the renin-angiotensin system?
 AU Waeber, B.; Nussberger, J.; Brunner, H. R.
 CS Div. Hypertens., Cent. Hosp. Univ. Vaudois, Lausanne, 1011, Switz.
 SO Annales d'Endocrinologie (1986), 47(3), 167-77
 CODEN: ANENAG; ISSN: 0003-4266
 DT Journal; General Review
 LA French

L13 ANSWER 412 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1986:455299 CAPLUS
 DN 105:55299
 TI Regulation of renin secretion in conscious adrenalectomized rats with glucocorticoid-induced hypertension
 AU Burris, J. F.; Waeber, B.; Nussberger, J.; Brunner, H. R.
 CS Div. Nephrol. Hypertens., Cent. Hosp. Univ. Vaudois, Lausanne, Switz.
 SO Archives Internationales de Pharmacodynamie et de Therapie (1986), 280(2), 292-301
 CODEN: AIPTAK; ISSN: 0003-9780
 DT Journal
 LA English

L13 ANSWER 413 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1986:161889 CAPLUS
 DN 104:161889
 TI Renal response to pentobarbital anesthesia in rats: effect of interrupting the renin-angiotensin system
 AU Walker, L. A.; Gellai, M.; Valtin, H.
 CS Dep. Physiol., Dartmouth Med. Sch., Hanover, NH, USA
 SO Journal of Pharmacology and Experimental Therapeutics (1986), 236(3), 721-8
 CODEN: JPETAB; ISSN: 0022-3565
 DT Journal
 LA English

L13 ANSWER 414 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:416618 CAPLUS
 DN 103:16618
 TI Effects of calcium-blockade and converting-enzyme inhibitor on regional blood flow in a conscious rat model of **heart failure**
 AU Drexler, H.; Truog, A. G.; Just, H.; Zelis, R.
 CS Abt. Innere Med. III, Universitaetsklin. Freiburg/Br., Freiburg/Br., Fed. Rep. Ger.
 SO Klinische Wochenschrift (1985), 63(6), 262-7
 CODEN: KLWOAZ; ISSN: 0023-2173
 DT Journal
 LA German

L13 ANSWER 415 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:400380 CAPLUS
 DN 103:380
 TI Effect of calcium blocker and converting enzyme inhibitor on organ perfusion in experimental cardiac insufficiency
 AU Drexler, H.; Truog, A. G.; Just, H.; Zelis, R.
 CS Univ. Freiburg/Br., Freiburg/Br., Fed. Rep. Ger.
 SO Verhandlungen der Deutschen Gesellschaft fuer Innere Medizin (1984), 90, Pt. 2, 1412-14
 CODEN: VDGIA2; ISSN: 0070-4067
 DT Journal
 LA German

L13 ANSWER 416 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:178913 CAPLUS
 DN 102:178913
 TI Aldosterone and prolactin responsiveness after prolonged treatment of congestive **heart failure** with **captopril**
 AU Jungmann, E.; Stoerger, H.; Althoff, P. H.; Hadler, D.; Fassbinder, W.; Bussmann, W. D.; Kaltenbach, M.; Schoeffling, K.
 CS Cent. Intern. Med., Johann Wolfgang Goethe-Univ., Frankfurt am Main, Fed. Rep. Ger.
 SO European Journal of Clinical Pharmacology (1985), 28(1), 1-4
 CODEN: EJCPAS; ISSN: 0031-6970
 DT Journal
 LA English

L13 ANSWER 417 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:142585 CAPLUS
 DN 102:142585
 TI Enalapril, a nonsulphydryl angiotensin-converting enzyme inhibitor
 AU Vlasses, Peter H.; Larijani, Ghassem E.; Conner, Dale P.; Ferguson, Roger K.
 CS Dep. Med., Jefferson Med. Coll., Philadelphia, PA, 19107, USA
 SO Clinical Pharmacy (1985), 4(1), 27-40
 CODEN: CPHADV; ISSN: 0278-2677
 DT Journal; General Review
 LA English

L13 ANSWER 418 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:110816 CAPLUS
 DN 102:110816
 TI Vasopressin and renin in high output **heart failure** of rats: hemodynamic effects of elevated plasma hormone levels
 AU Riegger, Guenter A. J.; Liebau, Gerhart; Bauer, Eberhard; Kochsiek, Kurt
 CS Med. Universitaetsklin., Wuerzburg, D-8700, Fed. Rep. Ger.
 SO Journal of Cardiovascular Pharmacology (1985), 7(1), 1-5
 CODEN: JPCPDT; ISSN: 0160-2446
 DT Journal

LA English

L13 ANSWER 419 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1984:604124 CAPLUS
 DN 101:204124
 TI Effects of **captopril** on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive **heart failure**
 AU Kubo, Shinichiro; Nishioka, Akinori; Nishimura, Hikaru; Kawamura, Keishiro; Takatsu, Tadasu
 CS Takatsuki, 569, Japan
 SO Clinical Pharmacology & Therapeutics (St. Louis, MO, United States) (1984), 36(4), 456-63
 CODEN: CLPTAT; ISSN: 0009-9236
 DT Journal
 LA English

L13 ANSWER 420 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1984:118850 CAPLUS
 DN 100:118850
 TI Role of the renin-angiotensin system in the development of congestive **heart failure** in the dog as assessed by chronic converting-enzyme blockade
 AU Riegger, Guenter A. J.; Liebau, Gerhart; Holzschuh, Matthias; Witkowski, Dorothea; Steilner, Hansgeorg; Kochsiek, Kurt
 CS Med. Universitaetsklin. Wuerzburg, Wuerzburg, D 8700, Fed. Rep. Ger.
 SO American Journal of Cardiology (1984), 53(4), 614-18
 CODEN: AJCDAG; ISSN: 0002-9149
 DT Journal
 LA English

L13 ANSWER 421 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1984:100495 CAPLUS
 DN 100:100495
 TI Regulation of angiotensin-converting enzyme
 AU Fyhrquist, Frej; Gronhagen-Riska, Carola; Hortling, Lars; Forslund, Terje; Tikkanen, Ilkka
 CS Minerva Inst. Med. Res., Helsinki, SF-00101/10, Finland
 SO Journal of Hypertension (1983), 1(Suppl. 1), 25-30
 CODEN: JOHYD3; ISSN: 0263-6352
 DT Journal
 LA English

L13 ANSWER 422 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1984:16 CAPLUS
 DN 100:16
 TI The clinical application of converting enzyme inhibitors
 AU Brunner, H. R.; Turini, G. A.; Waeber, B.; Nussberger, J.; Biollaz, J.
 CS Div. Nephrol. Hypertens., Cent. Hosp. Univ., Lausanne, Switz.
 SO Clinical and Experimental Hypertension, Part A: Theory and Practice (1983), A5(7-8), 1355-66
 CODEN: CEHADM; ISSN: 0730-0077
 DT Journal; General Review
 LA English

L13 ANSWER 423 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1983:468388 CAPLUS
 DN 99:68388
 TI Increased plasma arginine vasopressin levels in patients with congestive **heart failure**
 AU Goldsmith, Steven R.; Francis, Gary S.; Cowley, Allen W., Jr.; Levine, T. Barry; Cohn, Jay N.

AN 1997:168547 CAPLUS
 DN 126:152803
 TI Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**
 IN Alexander, John C.; Schuh, Joseph R.; Gorczynski, Richard J.
 PA G.D. Searle & Co., USA; Alexander, John C.; Schuh, Joseph R.; Gorczynski, Richard J.
 SO PCT Int. Appl., 218 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K045-06
 ICS A61K031-585
 CC 1-8 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640257	A1	19961219	WO 1996-US9335	19960605
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA			
	CA 2224079	AA	19961219	CA 1996-2224079	19960605
	AU 9661577	A1	19961230	AU 1996-61577	19960605
	AU 725689	B2	20001019		
	EP 831910	A1	19980401	EP 1996-919170	19960605
	EP 831910	B1	20011121		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	CN 1192697	A	19980909	CN 1996-196155	19960605
	BR 9609066	A	19990126	BR 1996-9066	19960605
	JP 11507627	T2	19990706	JP 1996-501678	19960605
	NZ 310730	A	20010126	NZ 1996-310730	19960605
	RU 2166330	C2	20010510	RU 1998-100250	19960605
	IL 122242	A1	20010724	IL 1996-122242	19960605
	AT 209047	E	20011215	AT 1996-919170	19960605
	ES 2167571	T3	20020516	ES 1996-919170	19960605
	RO 118046	B1	20030130	RO 1997-2272	19960605
	PL 185150	B1	20030331	PL 1996-324001	19960605
	NO 9705741	A	19980129	NO 1997-5741	19971205
PRAI	US 1995-486456	A	19950607		
	WO 1996-US9335	W	19960605		

OS MARPAT 126:152803

AB A combination therapy comprising a therapeutically-effective amt. of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amt. of an angiotensin II receptor antagonist is described for treatment of circulatory disorders, including cardiovascular disorders, e.g. hypertension and congestive **heart failure**.
 Preferred angiotensin II receptor antagonists are those compds. having high potency and bioavailability and which are characterized in having an imidazole or triazole moiety attached to a biphenylmethyl or pyridinyl/phenylmethyl moiety. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of 9.alpha.,11.alpha.-substituted epoxy moiety. A preferred combination therapy includes the angiotensin II receptor antagonist 5-[2-[5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole and the aldosterone receptor antagonist epoxymexrenone.
 ST angiotensin II antagonist combination cardiovascular disorder;
 epoxysteroid aldosterone antagonist combination cardiovascular disorder;

hypertension congestive **heart failure** therapeutic combination; cardiovascular disorder therapeutic combination; epoxymexrenone ATII antagonist combination cardiovascular disorder

IT Angiotensin receptor antagonists
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (angiotensin II; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT Antihypertensives
 Cardiovascular agents
 Drug delivery systems
 (epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT Mineralocorticoid receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT Steroids, biological studies
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (epoxy; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT **Heart, disease**
 (**failure**; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 141871-61-6, A 81282
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (A 81282; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 122088-76-0, CGP 38560A
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (CGP 38560A; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 135689-23-5, CGP 48369
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (CGP 48369; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 114798-36-6, DuP 167
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (DuP 167; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 153049-46-8, EXP 063
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (EXP 063; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 136042-19-8, FK 739
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (FK 739; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 138620-04-9, ICI-D 6888
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (ICI-D 6888; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 133240-72-9, L 158978
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (L 158978; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 154512-46-6, L 162441
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (L 162441; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 148564-45-8, LR-B 057
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (LR-B 057; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 154200-12-1, RWJ 46458
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (RWJ 46458; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 149285-55-2, WAY 126227
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (WAY 126227; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

IT 151406-07-4, YM 358
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (YM 358; epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive **heart failure**)

disorders, including congestive heart failure)

IT 34273-10-4, Saralasin 39698-78-7, Saralasin acetate 88874-29-7,
Sarmesin 95508-61-5, Isoteolin 95716-76-0 95716-78-2 95716-95-3
95716-96-4 95716-97-5 95716-98-6 95716-99-7 95717-01-4
95717-02-5 105186-68-3, KRI-1177 **107724-20-9** 114773-44-3,
EXP-6803 114785-12-5, PD-123177 114798-27-5, EXP-7711 114798-32-2,
EXP-9270 118393-93-4, S-8307 119256-78-9, S-8308 121280-51-1,
EXP-6155 124750-92-1, EXP-3174 124750-95-4, DuP-532 124750-99-8,
Losartan potassium 130663-39-7, PD-123319 133040-01-4, Eprosartan
133051-66-8 133051-78-2 133085-33-3, BIBS39 133240-46-7, L-158809
133690-62-7 133732-33-9 135015-84-8, ZD-8731 135070-05-2, E-4177
136284-47-4, CV-11194 137862-53-4, Valsartan 138402-11-6, Irbesartan
139476-18-9 139476-19-0 139476-20-3 139476-21-4 139476-22-5
139476-23-6 139476-24-7 139476-25-8 139476-26-9 139476-27-0
139476-28-1 139476-29-2 139476-30-5 139476-31-6 139476-32-7
139476-33-8 139476-34-9 139476-35-0 139476-37-2 139476-38-3
139476-40-7 139476-41-8 139476-42-9 139476-43-0 139481-59-7,
Candesartan 139501-60-3 139501-61-4 139501-62-5 139958-16-0,
ME-3221 139964-19-5, DMP-811 140120-40-7 140120-41-8 140120-42-9
140120-43-0 140120-44-1 140120-45-2 140120-46-3 140120-47-4
140120-48-5 140120-49-6 140120-50-9 140120-51-0 140120-52-1
140120-53-2 140120-54-3 140120-55-4 140120-56-5 140120-57-6
140120-58-7 140120-59-8 140120-60-1 140120-61-2 140120-62-3
140120-63-4 140120-64-5 140120-65-6 140120-66-7 140120-67-8
140120-68-9 140120-70-3 140120-71-4 140120-72-5 140120-73-6
140120-75-8 140120-76-9 140120-77-0 140120-78-1 140120-79-2
140120-80-5 140120-81-6 140120-82-7 140120-84-9 140120-86-1
140120-88-3 140120-89-4 140120-91-8 140120-93-0 140120-94-1
140120-96-3 140120-97-4 140120-98-5 140120-99-6 140121-00-2
140121-01-3 140121-02-4 140121-03-5 140121-04-6 140121-05-7
140121-06-8 140121-07-9 140121-08-0 140121-09-1 140121-10-4
140121-11-5 140121-14-8 140121-15-9 140121-16-0 140121-17-1
140121-18-2 140126-38-1 140157-30-8 140157-31-9 140157-32-0
140199-14-0 140199-15-1 140199-16-2 140199-17-3 140199-18-4
140199-19-5 140199-20-8 140199-21-9 140199-22-0 140199-23-1
140199-24-2 140199-26-4 140199-27-5 140199-48-0 140199-49-1
141386-89-2 141386-95-0 141387-00-0 141387-02-2 141387-42-0
141887-34-5, A-81988 142023-57-2, BIBS-222 142410-81-9 142410-86-4
142410-88-6 142410-89-7 142999-90-4, BMS-180560 143494-72-8,
ICI-D8731 143573-49-3 143573-50-6 143573-55-1 143573-56-2
143573-57-3 143573-58-4 144062-54-4 144062-55-5 144062-56-6
144062-57-7 144062-58-8 144062-59-9 144062-60-2 144062-61-3
144701-48-4, Telmisartan 144873-19-8 144873-21-2 144873-25-6
144873-32-5 145004-82-6, L-161177 145040-37-5, Candesartan cilexetil
145061-98-9 145062-04-0 145062-14-2 145160-47-0 145160-48-1
145160-49-2 145160-50-5 145160-51-6 145160-52-7 145160-53-8
145160-54-9 145160-55-0 145160-56-1 145160-57-2 145160-58-3
145160-59-4 145160-60-7 145160-61-8 145160-62-9 145160-63-0
145160-64-1 145160-65-2 145160-66-3 145160-67-4 145160-68-5
145160-69-6 145160-70-9 145160-71-0 145160-72-1 145160-73-2
145160-74-3 145160-75-4 145160-76-5 145160-77-6 145160-78-7
145160-79-8 145160-80-1 145160-81-2 145160-82-3 145160-83-4
145160-84-5 145160-85-6 145160-86-7 145160-87-8

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive heart failure)

IT 145160-88-9 145160-89-0 145216-03-1 145216-23-5 145216-43-9
145216-51-9 145216-54-2 145216-57-5 145216-83-7 145217-23-8
145217-63-6 145218-03-7 145543-03-9, RG-13647 145733-36-4,

Tasosartan 145781-32-4, Zolasartan 146623-69-0, Sapisartan
 146709-78-6, ZD-7155 146948-75-6, L 162234 148504-51-2, UP-269-6
 148564-47-0, LR-B/081 149586-24-3, YM 31472 149810-30-0 149968-26-3
 150438-02-1, CI-996 150484-27-8, L-159689 150802-50-9, KW 3433
 152134-03-7, U-97018 153072-63-0, BMS-184698 153235-15-5, HR-720
 153465-66-8, GA 0056 (pharmaceutical) 153804-05-8, KT3-671
 154668-27-6, LY-301875 155617-69-9 155617-70-2 155617-71-3
 155617-72-4 155961-06-1 155961-08-3 155961-10-7 155961-12-9
 157263-00-8, L-159282 158776-83-1 158776-84-2 160936-33-4, SL 910102
 165113-01-9 165113-02-0 165113-03-1 165113-04-2 165113-05-3
 165113-06-4 165113-07-5 165113-08-6 165113-09-7 165113-14-4
 169181-38-8, XR-510 169281-98-5, L-163017 172262-72-5 172345-25-4,
 RWJ-38970 173661-98-8 173661-99-9 173662-00-5 173662-01-6
 173662-02-7 173662-03-8 173662-04-9 173662-05-0 173662-06-1
 173662-07-2 173662-08-3 173662-09-4 173662-10-7 173662-11-8
 173662-12-9 173662-13-0 173662-14-1 173662-15-2 173662-16-3
 173662-17-4 173662-18-5 173662-19-6 173662-20-9 173662-21-0
 173662-22-1 173662-23-2 173662-24-3 173662-25-4 173662-26-5
 173662-27-6 173662-28-7 186453-50-9 186453-64-5 186453-72-5
 186453-73-6 186453-74-7 186453-75-8 186453-76-9 186453-77-0
 186453-78-1 186453-79-2 186453-80-5 186453-81-6 186453-82-7
 186453-83-8 186453-84-9 186453-85-0 186453-86-1 186453-87-2
 186453-88-3 186453-89-4 186453-90-7 186453-91-8 186453-92-9
 186453-93-0 186537-37-1, L 162154 186537-38-2, L 159874 186615-80-5,
 BIBR 363 186615-82-7, CGP 49870 186615-83-8, CGP 63170 186615-84-9,
 DA 2079 186615-85-0, DE 3489 186615-88-3, EMD 66397 186615-89-4, EMD
 73495 186615-91-8, EXP 929 186615-99-6, ICI-D 7155 186616-01-3, L
 163007 186616-03-5, LR-B 087 186616-04-6, LY 235656 186616-05-7, LY
 285434 186616-06-8, LY 302289 186616-07-9, LY 315995 186616-10-4, PD
 150304 186616-15-9, U 96849 186616-16-0, UP 275-22 186616-18-2, WK
 1360 186616-19-3, WK 1492.2K 186616-20-6, X 6803 186616-21-7, XH 148
 186817-55-0

RL: BAC (Biological activity or effector, except adverse); BPR (Biological
 process); BSU (Biological study, unclassified); THU (Therapeutic use);
 BIOL (Biological study); PROC (Process); USES (Uses)

(epoxy-steroidal aldosterone antagonist and angiotensin II antagonist
 combination therapy for treatment of cardiovascular disorders,
 including congestive **heart failure**)

IT 52-39-1, Aldosterone 11128-99-7, Angiotensin II

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (epoxy-steroidal aldosterone antagonist and angiotensin II antagonist
 combination therapy for treatment of cardiovascular disorders,
 including congestive **heart failure**)

=>


AN 1989:491242 CAPLUS
 DN 111:91242
 TI Atrial natriuretic peptide levels in congestive **heart failure** in man before and during converting enzyme inhibition
 AU Crozier, Ian G.; Nicholls, M. Gary; Ikram, Hamid; Espiner, Eric A.; Yandle, Tim G.
 CS Dep. Cardiol., Princess Margaret Hosp., Christchurch, N. Z.
 SO Clinical and Experimental Pharmacology and Physiology (1989), 16(5), 417-24
 CODEN: CEXPB9; ISSN: 0305-1870
 DT Journal
 LA English
 CC 2-10 (Mammalian Hormones)
 Section cross-reference(s): 14
 AB To det. the response of plasma atrial natriuretic peptide (ANP) to treatment with an angiotensin-converting enzyme (ACE) inhibitor in **heart failure**, patients were studied before and after the addn. of the ACE inhibitor **ramipril** to maintenance digoxin and diuretic treatment. Baseline arterial ANP levels were raised, but fell during **ramipril** treatment in parallel with changes in both hemodynamic recordings (arterial pressure, pulmonary artery diastolic pressure, and right atrial pressure) and hormone levels (angiotensin II and aldosterone). Coronary sinus ANP was greater than concomitant arterial levels, and the coronary sinus ANP secretion rate was calcd. to be in the range 15-119 pmol/min. Thus, an improvement in hemodynamic function during ACE inhibitor treatment is assocd. with a decline in elevated ANP levels, supporting the concept that atrial stretch or pressure regulates the secretion of atrial peptides in man.
 ST atriopeptin secretion **heart**; angiotensin converting enzyme
heart atriopeptin
 IT Blood pressure
 (angiotensin-converting enzyme inhibition effect on, in **heart failure** in human)
 IT Blood plasma
 (atriopeptin of, in **heart failure** in human, angiotensin-converting enzyme inhibition effect on)
 IT **Heart**, disease or disorder
 (**failure**, atriopeptin of blood plasma in, of human, angiotensin-converting enzyme inhibition effect on)
 IT 9015-82-1, Angiotensin-converting enzyme
 RL: BIOL (Biological study)
 (inhibition of, atriopeptin of blood plasma response to, in **heart failure** in human)
 IT 52-39-1, Aldosterone 9015-94-5, Renin, biological studies 11128-99-7, Angiotensin II 85637-73-6, Atrial natriuretic peptide
 RL: BIOL (Biological study)
 (of blood plasma, in **heart failure** in human, angiotensin converting enzyme inhibition effect on)

=>

AN 1990:151108 CAPLUS
 DN 112:151108
 TI **Ramipril**. A review of its pharmacological properties and
 therapeutic efficacy in cardiovascular disorders
 AU Todd, Peter A.; Benfield, Paul
 CS ADIS Drug Inf. Serv., ADIS Press Ltd., Auckland, N. Z.
 SO Drugs (1990), 39(1), 110-35
 CODEN: DRUGAY; ISSN: 0012-6667
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 AB A review, with 113 refs., on the pharmacol. of **ramipril** as an
 angiotensin-converting enzyme inhibitor and of the therapy of hypertension
 and congestive **heart failure** with **ramipril**.
 ST review **ramipril** pharmacol cardiovascular disorder
 IT Hypertension
 (therapy of, with **ramipril**, in humans and lab. animals)
 IT **Heart**, disease or disorder
 (**failure**, therapy of, with **ramipril**, in humans and
 lab. animals)
 IT 87333-19-5, **Ramipril**
 RL: BIOL (Biological study)
 (pharmacol. of and cardiovascular therapy with, in humans and lab.
 animals)

=>

AN 1981:400475 CAPLUS
 DN 95:475
 TI Effect of the angiotensin-converting enzyme inhibitor, **captopril**
 , on development of renal hypertension in rats
 AU Fregly, Melvin J.; Lockley, Ora E.; Simpson, Charles E.
 CS Dep. Physiol., Coll. Med., Gainesville, FL, 32610, USA
 SO Pharmacology (1981), 22(5), 277-85
 CODEN: PHMGBN; ISSN: 0031-7012
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 GI



AB Female rats (230-260 g) made hypertensive by bilateral renal encapsulation with latex envelopes were divided into 3 equal groups. Two groups were administered the angiotensin-converting enzyme inhibitor **captopril** (SQ 14,225) (I) [62571-86-2] in drinking water at a concn. sufficient to yield a dose of 25 and 50 mg/kg/day, resp. The 3rd group was untreated. A 4th group served as a normotensive control group. Systolic blood pressures and body wts. were measured weekly during a 4-wk control and an 8-wk exptl. period. Both doses prevented the elevation of blood pressure to the level of the untreated hypertensive controls. Blood pressure of the group receiving the higher dose of I was within the range of that of the normotensive control group by the end of the expt. while that of the group receiving the lower dose was between the blood pressures of untreated hypotensive and normotensive controls. Renal encapsulation resulted in **failure** of the rats to grow normally. Administration of I at either dose had no addnl. effect on body wt. To test whether inhibition of the angiotensin-converting enzyme occurred at the doses of I used, angiotensin I (200 .mu.g/kg, s.c.) and bradykinin (200 .mu.g/kg, s.c.) were administered sep. and their effects on water intakes of control and I-treated groups tested. I inhibited the drinking response to angiotensin I while increasing it in response to bradykinin. The pressor response following i.v. administration of 1.25 .mu.g angiotensin I/kg to anesthetized rats was also studied. The groups treated with I had a significantly reduced response to angiotensin I compared with those of either normotensive groups. Apparently, inhibition of the angiotensin-converting enzyme occurred at both doses of I with the higher dose inducing a somewhat greater inhibition. At autopsy, **heart** wt. of the group receiving the higher dose of I was significantly less than that of the untreated hypertensive group, but significantly greater than that of the normotensive group. Apparently, I at the doses used, provided significant protection against elevation of blood pressure in renal hypertensive rats.

ST **captopril** renal hypertension; angiotensin converting enzyme inhibitor hypertension

IT 62571-86-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antihypertensive activity of, in renal hypertension)

AN 1980:103819 CAPLUS
DN 92:103819
TI **Captopril** in the treatment of clinical hypertension and cardiac
failure
AU Atkinson, A. B.; Robertson, J. I. S.
CS MRC Blood Pressure Unit, Western Infirm., Glasgow, G11 6NT, UK
SO Lancet (1979), 2(8147), 836-9
CODEN: LANCAO; ISSN: 0023-7507
DT Journal; General Review
LA English
CC 1-0 (Pharmacodynamics)
AB A review, with 78 refs., discussing **captopril** [62571-86-2]
therapeutics in clin. hypertension and **heart failure**.
ST **captopril** hypertension **heart failure** review
IT Hypertension
(**captopril** effect on)
IT **Heart**, disease or disorder
(**failure**, **captopril** effect on)
IT 62571-86-2
RL: BIOL (Biological study)
(hypertension and **heart failure** treatment with)

=>

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003003012	A1	20030109	WO 2002-AU856	20020628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	AU 2001-5986 A 20010629				
OS	MARPAT 138:86096				
RE.CNT	2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L9 ANSWER 15 OF 17 CA COPYRIGHT 2003 ACS on STN
 AN 138:70103 CA
 TI The new bioactive diterpenes cyanthiwigins E-AA from the Jamaican sponge
 Myrmekioderma styx
 AU Peng, Jiangnan; Walsh, Kelly; Weedman, Valarie; Bergthold, Jennifer D.;
 Lynch, John; Lieu, Kuo L.; Braude, Irwin A.; Kelly, Michelle; Hamann, Mark
 T.
 CS School of Pharmacy, Department of Pharmacognosy and National Center for
 Natural Products Research, University of Mississippi, MS, 38677, USA
 SO Tetrahedron (2002), 58(39), 7809-7819
 CODEN: TETRAB; ISSN: 0040-4020
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 17 CA COPYRIGHT 2003 ACS on STN
 AN 138:55742 CA
 TI Preparation of diamines and their use as chemokine receptor CXCR4
 antagonists, anti-HIV, anti-AIDS, and antitumor agents
 IN Kamiyama, Keiji; Kanzaki, Naoyuki; Hasuoka, Atsushi; Mochizuki, Manabu;
 Kawamoto, Tetsuji
 PA Takeda Chemical Industries, Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 84 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002371042	A2	20021226	JP 2001-177827	20010612
PRAI	JP 2001-177827 20010612				
OS	MARPAT 138:55742				

L9 ANSWER 17 OF 17 CA COPYRIGHT 2003 ACS on STN
 AN 138:32788 CA
 TI Inhibition of cytopathic effect of human immunodeficiency virus
 type-1 by various phorbol derivatives
 AU El-Mekkawy, Sahar; Meselhy, Meselhy Ragab; Abdel-Hafez, Atef Abdel-Monem;
 Nakamura, Norio; Hattori, Masao; Kawahata, Takuya; Otake, Toru
 CS Institute of Natural Medicine, Toyama Medical and Pharmaceutical
 University, Toyama, 930-0194, Japan
 SO Chemical & Pharmaceutical Bulletin (2002), 50(4), 523-529




AN 1980:103819 CAPLUS
DN 92:103819
TI **Captopril** in the treatment of clinical hypertension and cardiac
failure
AU Atkinson, A. B.; Robertson, J. I. S.
CS MRC Blood Pressure Unit, Western Infirm., Glasgow, G11 6NT, UK
SO Lancet (1979), 2(8147), 836-9
CODEN: LANCAO; ISSN: 0023-7507
DT Journal; General Review
LA English
CC 1-0 (Pharmacodynamics)
AB A review, with 78 refs., discussing **captopril** [62571-86-2]
therapeutics in clin. hypertension and **heart failure**.
ST **captopril** hypertension **heart failure** review
IT Hypertension
(**captopril** effect on)
IT **Heart**, disease or disorder
(**failure**, **captopril** effect on)
IT 62571-86-2
RL: BIOL (Biological study)
(hypertension and **heart failure** treatment with)

=>

AN 1989:491242 CAPLUS
 DN 111:91242
 TI Atrial natriuretic peptide levels in congestive **heart failure** in man before and during converting enzyme inhibition
 AU Crozier, Ian G.; Nicholls, M. Gary; Ikram, Hamid; Espiner, Eric A.; Yandle, Tim G.
 CS Dep. Cardiol., Princess Margaret Hosp., Christchurch, N. Z.
 SO Clinical and Experimental Pharmacology and Physiology (1989), 16(5), 417-24
 CODEN: CEXPB9; ISSN: 0305-1870
 DT Journal
 LA English
 CC 2-10 (Mammalian Hormones)
 Section cross-reference(s): 14
 AB To det. the response of plasma atrial natriuretic peptide (ANP) to treatment with an angiotensin-converting enzyme (ACE) inhibitor in **heart failure**, patients were studied before and after the addn. of the ACE inhibitor **ramipril** to maintenance digoxin and diuretic treatment. Baseline arterial ANP levels were raised, but fell during **ramipril** treatment in parallel with changes in both hemodynamic recordings (arterial pressure, pulmonary artery diastolic pressure, and right atrial pressure) and hormone levels (angiotensin II and aldosterone). Coronary sinus ANP was greater than concomitant arterial levels, and the coronary sinus ANP secretion rate was calcd. to be in the range 15-119 pmol/min. Thus, an improvement in hemodynamic function during ACE inhibitor treatment is assocd. with a decline in elevated ANP levels, supporting the concept that atrial stretch or pressure regulates the secretion of atrial peptides in man.
 ST atriopeptin secretion **heart**; angiotensin converting enzyme **heart** atriopeptin
 IT Blood pressure
 (angiotensin-converting enzyme inhibition effect on, in **heart failure** in human)
 IT Blood plasma
 (atriopeptin of, in **heart failure** in human, angiotensin-converting enzyme inhibition effect on)
 IT **Heart**, disease or disorder
 (**failure**, atriopeptin of blood plasma in, of human, angiotensin-converting enzyme inhibition effect on)
 IT 9015-82-1, Angiotensin-converting enzyme
 RL: BIOL (Biological study)
 (inhibition of, atriopeptin of blood plasma response to, in **heart failure** in human)
 IT 52-39-1, Aldosterone 9015-94-5, Renin, biological studies 11128-99-7, Angiotensin II 85637-73-6, Atrial natriuretic peptide
 RL: BIOL (Biological study)
 (of blood plasma, in **heart failure** in human, angiotensin converting enzyme inhibition effect on)

=>

AN 1981:400475 CAPLUS
 DN 95:475
 TI Effect of the angiotensin-converting enzyme inhibitor, **captopril**
 , on development of renal hypertension in rats
 AU Fregly, Melvin J.; Lockley, Ora E.; Simpson, Charles E.
 CS Dep. Physiol., Coll. Med., Gainesville, FL, 32610, USA
 SO Pharmacology (1981), 22(5), 277-85
 CODEN: PHMGBN; ISSN: 0031-7012
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 GI



AB Female rats (230-260 g) made hypertensive by bilateral renal encapsulation with latex envelopes were divided into 3 equal groups. Two groups were administered the angiotensin-converting enzyme inhibitor **captopril** (SQ 14,225) (I) [62571-86-2] in drinking water at a concn. sufficient to yield a dose of 25 and 50 mg/kg/day, resp. The 3rd group was untreated. A 4th group served as a normotensive control group. Systolic blood pressures and body wts. were measured weekly during a 4-wk control and an 8-wk exptl. period. Both doses prevented the elevation of blood pressure to the level of the untreated hypertensive controls. Blood pressure of the group receiving the higher dose of I was within the range of that of the normotensive control group by the end of the expt. while that of the group receiving the lower dose was between the blood pressures of untreated hypotensive and normotensive controls. Renal encapsulation resulted in **failure** of the rats to grow normally. Administration of I at either dose had no addnl. effect on body wt. To test whether inhibition of the angiotensin-converting enzyme occurred at the doses of I used, angiotensin I (200 .mu.g/kg, s.c.) and bradykinin (200 .mu.g/kg, s.c.) were administered sep. and their effects on water intakes of control and I-treated groups tested. I inhibited the drinking response to angiotensin I while increasing it in response to bradykinin. The pressor response following i.v. administration of 1.25 .mu.g angiotensin I/kg to anesthetized rats was also studied. The groups treated with I had a significantly reduced response to angiotensin I compared with those of either normotensive groups. Apparently, inhibition of the angiotensin-converting enzyme occurred at both doses of I with the higher dose inducing a somewhat greater inhibition. At autopsy, **heart** wt. of the group receiving the higher dose of I was significantly less than that of the untreated hypertensive group, but significantly greater than that of the normotensive group. Apparently, I at the doses used, provided significant protection against elevation of blood pressure in renal hypertensive rats.

ST **captopril** renal hypertension; angiotensin converting enzyme inhibitor hypertension

IT 62571-86-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antihypertensive activity of, in renal hypertension)

CS Dep. Physiol., Med. Coll. Wisconsin, Milwaukee, WI, USA
 SO Journal of the American College of Cardiology (1983), 1(6), 1385-90
 CODEN: JACCDI; ISSN: 0735-1097
 DT Journal
 LA English

L13 ANSWER 424 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1983:155037 CAPLUS
 DN 98:155037
 TI Prevention of the development of **heart failure** and the regression of cardiac hypertrophy by **captopril** in the spontaneously hypertensive rat
 AU Pfeffer, J. M.; Pfeffer, M. A.; Mirsky, I.; Braunwald, E.
 CS Harvard Med. Sch., Brigham and Women's Hosp., Boston, MA, 02115, USA
 SO European Heart Journal (1983), 4(Suppl. A), 143-8
 CODEN: EHJODF; ISSN: 0195-668X
 DT Journal
 LA English

L13 ANSWER 425 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1983:118986 CAPLUS
 DN 98:118986
 TI **Captopril**: an update review of its pharmacological properties and therapeutic efficacy in congestive **heart failure**
 AU Romankiewicz, J. A.; Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S.
 CS Drug Inf. Serv., ADIS, Auckland, N. Z.
 SO Drugs (1983), 25(1), 6-40
 CODEN: DRUGAY; ISSN: 0012-6667
 DT Journal; General Review
 LA English

L13 ANSWER 426 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1982:210679 CAPLUS
 DN 96:210679
 TI Hemodynamic effects of **captopril** in essential hypertension, renovascular hypertension and cardiac **failure**: correlations with short- and long-term effects on plasma renin
 AU Wenting, G. J.; de Bruyn, J. H. B.; Man in't Veld, A. J.; Woittiez, A. J. J.; Derkx, F. H. M.; Schalekamp, Maarten A. D. H.
 CS Dep. Intern. Med., Erasmus Univ., Rotterdam, Neth.
 SO American Journal of Cardiology (1982), 49(6), 1453-9
 CODEN: AJCDAG; ISSN: 0002-9149
 DT Journal
 LA English

L13 ANSWER 427 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1982:135116 CAPLUS
 DN 96:135116
 TI **Captopril**: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive **heart failure**
 AU Vlasses, Peter H.; Ferguson, Roger K.; Chatterjee, Kanu
 CS Jefferson Med. Coll., Thomas Jefferson Univ., Philadelphia, PA, 19107, USA
 SO Pharmacotherapy (1982), 2(1), 1-17
 CODEN: PHPYDQ; ISSN: 0277-0008
 DT Journal; General Review
 LA English

L13 ANSWER 428 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1982:29257 CAPLUS
 DN 96:29257
 TI Evidence against an interaction of angiotensin II with the sympathetic

nervous system in man

AU Nicholls, M. G.; Espiner, E. A.; Miles, D. K.; Zweifler, A. J.; Julius, S.
 CS Endocrinol. Dep., Princess Margaret Hosp., Christchurch, N. Z.
 SO Clinical Endocrinology (Oxford, United Kingdom) (1981), 15(5), 423-30
 CODEN: CLECAP; ISSN: 0300-0664
 DT Journal
 LA English

L13 ANSWER 429 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:597316 CAPLUS
 DN 95:197316
 TI The effect of **captopril** on plasma histamine and histamine release in vitro
 AU Taylor, K. M.; Sharpe, D. N.
 CS Sch. Med., Univ. Auckland, Auckland, N. Z.
 SO Agents and Actions (1981), 11(5), 448-53
 CODEN: AGACBH; ISSN: 0065-4299
 DT Journal
 LA English

L13 ANSWER 430 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:400475 CAPLUS
 DN 95:475
 TI Effect of the angiotensin-converting enzyme inhibitor, **captopril**, on development of renal hypertension in rats
 AU Fregly, Melvin J.; Lockley, Ora E.; Simpson, Charles E.
 CS Dep. Physiol., Coll. Med., Gainesville, FL, 32610, USA
 SO Pharmacology (1981), 22(5), 277-85
 CODEN: PHMGBN; ISSN: 0031-7012
 DT Journal
 LA English

L13 ANSWER 431 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:150497 CAPLUS
 DN 94:150497
 TI Hemodynamic, hormonal, and electrolyte responses to **captopril** in resistant **heart failure**
 AU Maslowski, A. H.; Ikram, H.; Nicholls, M. G.; Espiner, E. A.
 CS Cardiol. Dep., Princess Margaret Hosp., Christchurch, N. Z.
 SO Lancet (1981), 1(8211), 71-4
 CODEN: LANCAO; ISSN: 0023-7507
 DT Journal
 LA English

L13 ANSWER 432 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:114654 CAPLUS
 DN 94:114654
 TI Low-dose **captopril** in chronic **heart failure**: acute hemodynamic effects and long-term treatment
 AU Sharpe, D. N.; Coxon, R. J.; Douglas, J. E.; Long, B.
 CS Dep. Med., Univ. Auckland Sch. Med., Auckland, N. Z.
 SO Lancet (1980), 2(8205), 1154-7
 CODEN: LANCAO; ISSN: 0023-7507
 DT Journal
 LA English

L13 ANSWER 433 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:58386 CAPLUS
 DN 94:58386
 TI Hyponatremia in congestive **heart failure** during treatment with **captopril**
 AU Nicholls, M. G.; Espiner, E. A.; Ikram, H.; Maslowski, A. H.

CS Endocrinol. Dep., Princess Margaret Hosp., Christchurch, N. Z.
 SO British Medical Journal (1980), 281(6245), 909
 CODEN: BMJOAE; ISSN: 0007-1447
 DT Journal
 LA English

L13 ANSWER 434 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:25151 CAPLUS
 DN 94:25151
 TI **Captopril**: an oral angiotensin converting enzyme inhibitor
 active in man
 AU Brunner, H. R.; Gavras, H.; Waeber, B.; Turini, G. A.; Wauters, J. P.
 CS Dep. Med., Cent. Hosp. Univ., Lausanne, 1011, Switz.
 SO Archives Internationales de Pharmacodynamie et de Therapie (1980),
 (Suppl., Symp.: Clin. Pharmacol. Antihypertens. Agents, 1979), 188-212
 CODEN: AIPTAK; ISSN: 0003-9780
 DT Journal
 LA English

L13 ANSWER 435 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1980:103819 CAPLUS
 DN 92:103819
 TI **Captopril** in the treatment of clinical hypertension and cardiac
failure
 AU Atkinson, A. B.; Robertson, J. I. S.
 CS MRC Blood Pressure Unit, Western Infirm., Glasgow, G11 6NT, UK
 SO Lancet (1979), 2(8147), 836-9
 CODEN: LANCAO; ISSN: 0023-7507
 DT Journal; General Review
 LA English

=> e hypertension

E1	2	HYPERTENSIO/BI
E2	3	HYPERTENSIOTENIC/BI
E3	62537 -->	HYPERTENSION/BI
E4	1	HYPERTENSION1/BI
E5	1	HYPERTENSION3/BI
E6	2	HYPERTENSION5/BI
E7	3	HYPERTENSIONAL/BI
E8	1	HYPERTENSIONC/BI
E9	1	HYPERTENSIONDESPITE/BI
E10	1	HYPERTENSIONIN/BI
E11	1	HYPERTENSIONMAY/BI
E12	1	HYPERTENSIONN/BI

=> s e3

L14 62537 HYPERTENSION/BI

=> d his

(FILE 'HOME' ENTERED AT 11:42:30 ON 16 SEP 2003)

FILE 'REGISTRY' ENTERED AT 11:42:39 ON 16 SEP 2003

L1 1 S EPLERENONE

FILE 'CAPLUS' ENTERED AT 11:43:07 ON 16 SEP 2003

	E HEART
L2	277174 S E3
L3	85 S L1
L4	53 S L2 AND L3
	E FAILURE

L5 148245 S E3
 L6 41 S L4 AND L5
 E CAPTOPRIL
 L7 6439 S E3
 L8 5 S L6 AND L7
 L9 6434 S L7 NOT L8
 L10 36 S L6 NOT L8
 E E RAMIPRIL
 E RAMIPRIL
 L11 852 S E3
 L12 1438 S L7 AND L2
 L13 435 S L12 AND L5
 E HYPERTENSION
 L14 62537 S E3

=> s l11 and l2

L15 338 L11 AND L2

=> s l15 and l5

L16 133 L15 AND L5

=> d l16 100-133

L16 ANSWER 100 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:312826 CAPLUS
 DN 129:50071
 TI Effects of endothelin receptor antagonism and angiotensin-converting
 enzyme inhibition on cardiac and renal remodeling in the rat
 AU Willette, Robert N.; Minehart, Heather; Ellison, Julie; Simons, Tawana;
 Short, Brian; Pullen, Mark; Ohlstein, Eliot H.; Nambi, Ponnal
 CS Department of Cardiovascular Pharmacology, SmithKline Beecham
 Pharmaceuticals, King of Prussia, PA, 19406, USA
 SO Journal of Cardiovascular Pharmacology (1998), 31(Suppl. 1, Endothelin V),
 S277-S283
 CODEN: JCPCDT; ISSN: 0160-2446
 PB Lippincott-Raven Publishers
 DT Journal
 LA English
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 101 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:136329 CAPLUS
 TI Development of **heart failure** following isoproterenol
 administration in the rat: role of the renin-angiotensin system
 AU Grimm, Daniel; Elsner, Dietmar; Schunkert, Heribert; Pfeifer, Michael;
 Griese, Daniel; Bruckschlegel, Gunter; Muders, Frank; Riegger, Gunter A.
 J.; Kromer, Eckhard P.
 CS Klinik und Poliklinik fur Innere Medizin II, Universitat Regensburg,
 Regensburg, D-93042, Germany
 SO Cardiovascular Research (1998), 37(1), 91-100
 CODEN: CVREAU; ISSN: 0008-6363
 PB Elsevier Science B.V.
 DT Journal
 LA English
 RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 102 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:177 CAPLUS
 DN 128:30250
 TI Effect of **ramipril** on **heart** rate variability in

digitalis-treated patients with chronic **heart failure**
 AU Guedon-Moreau, L.; Pinaud, A.; Logier, R.; Caron, J.; Lekieffre, J.;
 Dupuis, B.; Libersa, C. H.
 CS Faculte de Medecine, Service de Pharmacologie Hospitaliere, Lille, 59045,
 Fr.
 SO Cardiovascular Drugs and Therapy (1997), 11(4), 531-536
 CODEN: CDTHET; ISSN: 0920-3206
 PB Kluwer Academic Publishers
 DT Journal
 LA English

RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 103 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:725378 CAPLUS
 DN 128:57241
 TI Selective induction of the creatine kinase-B gene in chronic volume
 overload hypertrophy is not affected by ACE-inhibitor therapy
 AU Schultz, David; Su, Xuefeng; Bishop, Sanford P.; Billadello, Joseph;
 Dell'italia, Louis J.
 CS Birmingham Veteran Affairs Medical Center, Department of Medicine,
 Division of Cardiovascular Disease, Hypertension and Vascular Biology,
 University of Alabama at Birmingham, University Station, Birmingham, AL,
 35294, USA
 SO Journal of Molecular and Cellular Cardiology (1997), 29(10), 2665-2673
 CODEN: JMCDAY; ISSN: 0022-2828
 PB Academic
 DT Journal
 LA English

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 104 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:632471 CAPLUS
 DN 127:288179
 TI Use of amlodipine for the treatment and prophylaxis of congestive cardiac
failure of non-ischemic origin
 IN Cropp, Anne B.
 PA Pfizer Inc., USA
 SO Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 795327	A1	19970917	EP 1997-301472	19970305
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5948799	A	19990907	US 1997-815528	19970312
	CA 2199888	AA	19970915	CA 1997-2199888	19970313
	AU 9716307	A1	19970918	AU 1997-16307	19970314
	AU 713842	B2	19991209		
	JP 10007566	A2	19980113	JP 1997-61153	19970314
	JP 2918512	B2	19990712		
	ZA 9702228	A	19980914	ZA 1997-2228	19970314
	NZ 314411	A	20000623	NZ 1997-314411	19970314
PRAI	US 1996-13593P	P	19960315		

L16 ANSWER 105 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:387719 CAPLUS
 DN 127:60404
 TI Follow-up study of patients randomly allocated **ramipril** or

placebo for **heart failure** after acute myocardial
 infarction: AIRE extension (AIREX) study
 AU Hall, Alistair S.; Murray, Gordon D.; Ball, Stephen G.
 CS Institute for Cardiovascular Research, The Yorkshire Heart Centre,
 University of Leeds, Leeds, LS2 9JT, UK
 SO Lancet (1997), 349(9064), 1493-1497
 CODEN: LANCAO; ISSN: 0140-6736
 PB Lancet
 DT Journal
 LA English

L16 ANSWER 106 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:259996 CAPLUS
 DN 126:325243
 TI Effects of angiotensin-converting enzyme inhibitors and angiotensin II
 type 1 receptor antagonists in rats with **heart failure**
 : role of kinins and angiotensin II type 2 receptors
 AU Liu, Yun-He; Yang, Xiao-Ping; Sharov, Victor G.; Nass, Omar; Sabbah, Hani
 N.; Peterson, Edward; Carretero, Oscar A.
 CS Dep. Medicine, Henry Ford Hospital, Detroit, MI, 48202, USA
 SO Journal of Clinical Investigation (1997), 99(8), 1926-1935
 CODEN: JCINAO; ISSN: 0021-9738
 PB Rockefeller University Press
 DT Journal
 LA English

L16 ANSWER 107 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:97947 CAPLUS
 DN 126:194691
 TI ACE inhibitors in the treatment of **heart failure**:
 special emphasis on **ramipril**
 AU Lubsen, Jacobus
 CS SOCAR Research SA, Domaine de Leydefeur, Givrins, Switz.
 SO Reviews in Contemporary Pharmacotherapy (1996), 7(1), 15-22
 CODEN: RCPHFW; ISSN: 0954-8602
 PB Marius Press
 DT Journal; General Review
 LA English

L16 ANSWER 108 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:74276 CAPLUS
 DN 126:166266
 TI Effect of **ramipril** on morbidity and mode of death among
 survivors of acute myocardial infarction with clinical evidence of
heart failure
 AU Cleland, J. G. F.; Erhardt, L.; Murray, G.; Hall, A. S.; Ball, S. G.
 CS Medical Research Council Research Initiative in Heart Failure West Medical
 Building, University of Glasgow, Glasgow, UK
 SO European Heart Journal (1997), 18(1), 41-51
 CODEN: EHJODF; ISSN: 0195-668X
 PB Saunders
 DT Journal
 LA English

L16 ANSWER 109 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:70684 CAPLUS
 DN 126:139676
 TI Angiotensin-converting enzyme inhibitor therapy affects left ventricular
 mass in patients with ejection fraction >40% after acute myocardial
 infarction
 AU Johnson, David B.; Foster, Robert E.; Barilla, Francesco; Blackwell,
 Gerald G.; Roney, Maryann; Stanley, Alfred W. H., Jr.; Kirk, Kathy; Orr,

Roger A.; van der Geest, Rob J.; Reiber, Johan H. C.; Dell'Italia, Louis
 CS Birmingham Veteran Affairs Med. Cent., Univ. Alabama, Birmingham, AL, USA
 SO Journal of the American College of Cardiology (1997), 29(1), 49-54
 CODEN: JACCDI; ISSN: 0735-1097
 PB Elsevier
 DT Journal
 LA English

L16 ANSWER 110 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:661165 CAPLUS
 DN 125:284988
 TI Composition containing amlodipine, or a salt or felodipine and an ACE inhibitor
 IN Cropp, Anne B.; Kraska, Allen R.
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9628185	A2	19960919	WO 1996-IB145	19960226
	WO 9628185	A3	19961017		
	W: CA, FI, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2215234	AA	19960919	CA 1996-2215234	19960226
	CA 2215234	C	20011211		
	EP 804229	A2	19971105	EP 1996-901940	19960226
	EP 804229	B1	20030326		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	JP 11500140	T2	19990106	JP 1996-527415	19960226
	AT 235251	E	20030415	AT 1996-901940	19960226
	FI 9703691	A	19970915	FI 1997-3691	19970915
	US 6245787	B1	20010612	US 1998-894800	19980226
PRAI	US 1995-405108	A	19950316		
	WO 1996-IB145	W	19960226		

L16 ANSWER 111 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:616309 CAPLUS
 DN 125:257217
 TI Combination of angiotensin-converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
 IN MacLaughlan, Todd E.; Perez, Alfonso T.
 PA G.D. Searle and Co., USA
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9624372	A2	19960815	WO 1996-US1764	19960209
	WO 9624372	A3	19960926		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE				
	CA 2212712	AA	19960815	CA 1996-2212712	19960209
	AU 9648661	A1	19960827	AU 1996-48661	19960209

EP 808171	A2	19971126	EP 1996-904600	19960209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
CN 1180313	A	19980429	CN 1996-193013	19960209
BR 9607612	A	19980609	BR 1996-7612	19960209
JP 10513472	T2	19981222	JP 1996-524442	19960209
NZ 302578	A	20010525	NZ 1996-302578	19960209
EP 1201248	A2	20020502	EP 2001-128866	19960209
EP 1201248	A3	20020508		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
NZ 510572	A	20021126	NZ 1996-510572	19960209
PRAI US 1995-386858	A2	19950210		
EP 1996-904600	A3	19960209		
WO 1996-US1764	W	19960209		

L16 ANSWER 112 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:609926 CAPLUS
DN 125:257216
TI Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
IN MacLaughlan, Todd E.; Perez, Alfonso T.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9624373	A2	19960815	WO 1996-US1969	19960209
	WO 9624373	A3	19960926		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE				
	CA 2212713	AA	19960815	CA 1996-2212713	19960209
	AU 9653541	A1	19960827	AU 1996-53541	19960209
	EP 808172	A2	19971126	EP 1996-910309	19960209
	EP 808172	B1	20030625		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	CN 1180314	A	19980429	CN 1996-193030	19960209
	BR 9604882	A	19980519	BR 1996-4882	19960209
	JP 11507012	T2	19990622	JP 1996-524487	19960209
	NZ 305528	A	20010525	NZ 1996-305528	19960209
	EP 1136078	A2	20010926	EP 2001-116593	19960209
	EP 1136078	A3	20020724		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	AT 243529	E	20030715	AT 1996-910309	19960209
	US 2003148960	A1	20030807	US 2002-264639	20021004
PRAI US 1995-386852	A2	19950210			
EP 1996-910309	A3	19960209			
WO 1996-US1969	W	19960209			
US 1996-727201	A1	19961008			

L16 ANSWER 113 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:383294 CAPLUS
DN 125:48863
TI Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the **heart** of rats with renal **failure**: The effects of **ramipril**, nifedipine and moxonidine
AU Toernig, Johannes; Amann, Kerstin; Ritz, Eberhard; Nichols, Cornelia;

Zeier, Martin; Mall, Gerhard
 CS Department Internal Medicine, Ruperto Carola University, Heidelberg,
 D-69120, Germany
 SO Journal of the American Society of Nephrology (1996), 7(5), 667-675
 CODEN: JASNEU; ISSN: 1046-6673
 PB Williams & Wilkins
 DT Journal
 LA English

L16 ANSWER 114 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:315913 CAPLUS
 DN 125:960
 TI Angiotensin-converting enzyme inhibition, autonomic activity, and
 hemodynamics in patients with **heart failure** who
 perform isometric exercise
 AU Willenbrock, Roland; Oezcelik, Cemil; Osterziel, Karl-Josef; Dietz, Rainer
 CS Laboratory Experimental Heart Failure LEH, Franz-Volhard-Klinik/Max-
 Delbrück-Centrum, Berlin, 13125, Germany
 SO American Heart Journal (1996), 131(5), 999-1006
 CODEN: AHJOA2; ISSN: 0002-8703
 PB Mosby-Year Book
 DT Journal
 LA English

L16 ANSWER 115 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:292085 CAPLUS
 DN 124:332364
 TI Treatment with angiotensin-converting-enzyme inhibitor for
 epirubicin-induced dilated cardiomyopathy
 AU Jensen, B. V.; Nielsen, S. L.; Skovsgaard, T.
 CS Herlev Hospital, University Copenhagen, Herlev, DK-2730, Den.
 SO Lancet (1996), 347(8997), 297-299
 CODEN: LANCAO; ISSN: 0140-6736
 PB Lancet
 DT Journal
 LA English

L16 ANSWER 116 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:283379 CAPLUS
 DN 125:863
 TI Ongoing clinical trials of angiotensin-converting enzyme inhibitors for
 treatment of coronary artery disease in patients with preserved left
 ventricular function
 AU Pepine, Carl J.
 CS School of Medicine, University of Florida, Gainesville, FL, USA
 SO Journal of the American College of Cardiology (1996), 27(5), 1048-1052
 CODEN: JACCDI; ISSN: 0735-1097
 PB Elsevier
 DT Journal
 LA English

L16 ANSWER 117 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:235602 CAPLUS
 DN 124:306154
 TI Neurohormonal activation and congestive **heart failure**:
 Today's experience with ACE inhibitors and rationale for their use
 AU Sigurdsson, A.; Swedberg, K.
 CS Department Medicine, Ostra University Hospital, Goeteborg, Swed.
 SO European Heart Journal (1995), 16(Suppl. N, Heart Failure 95), 65-72
 CODEN: EHJODF; ISSN: 0195-668X
 PB Saunders
 DT Journal; General Review

LA English

L16 ANSWER 118 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:160830 CAPLUS
DN 124:278508
TI Mega-trials: Is meta-analysis an alternative?
AU Lubsen, J.
CS SOCAR Research SA, Givrins, CH-1271, Switz.
SO European Journal of Clinical Pharmacology (1996), 49(Suppl. 1), S29-S33
CODEN: EJCPAS; ISSN: 0031-6970
PB Springer
DT Journal
LA English

L16 ANSWER 119 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:64980 CAPLUS
DN 124:97758
TI Drug combination containing .alpha.-lipoic acid and cardiovascular agents
IN Weischer, Carl; Ulrich, Heinz; Conrad, Frank; Schmidt, Karlheinz
PA ASTA Medica AG, Germany
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 4420102	A1	19951214	DE 1994-4420102	19940609
PRAI	DE 1994-4420102		19940609		

L16 ANSWER 120 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:341410 CAPLUS
DN 122:122772
TI Relative effects of .alpha.1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog
AU McDonald, Kenneth M.; Garr, Michael; Carlyle, Peter F.; Francis, Gary S.; Hauer, Kate; Hunter, David W.; Parish, Todd; Stillman, Arthur; Cohn, Jay N.
CS Medical School, University of Minnesota, Minneapolis, MN, 55455, USA
SO Circulation (1994), 90(6), 3034-46
CODEN: CIRCAZ; ISSN: 0009-7322
DT Journal
LA English

L16 ANSWER 121 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:308218 CAPLUS
DN 122:71704
TI **Ramipril** prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency
AU Hropot, H.; Groetsch, H.; Klaus, E.; Langer, K. H.; Linz, W.; Wiemer, G.; Schoelkens, B. A.
CS SBU Cardiovascular Agents, Hoechst AG, Frankfurt/Main, D-65926, Germany
SO Naunyn-Schmiedeberg's Archives of Pharmacology (1994), 350(6), 646-52
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer
DT Journal
LA English

L16 ANSWER 122 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:124503 CAPLUS

DN 120:124503
 TI Pharmacodynamics of **ramipril**, piretanide, and their combination
 in volunteers with normal kidney function
 AU Fritschka, E.; Wiewer, J.; Eich, R.; Wagner, K.; Pooth, R.; Philipp, T.
 CS Dep. Intern. Med., Univ. Hosp. Essen, Essen, 4300/1, Germany
 SO International Congress Series (1993), 1023(Diuretics IV), 613-16
 CODEN: EXMDA4; ISSN: 0531-5131
 DT Journal
 LA English

L16 ANSWER 123 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1992:440438 CAPLUS

DN 117:40438

TI Synergistic therapeutic compositions for lowering blood pressure and
 treating congestive **heart failure**

IN Fossa, Anthony Andrea

PA Pfizer Inc., USA

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9117771	A1	19911128	WO 1991-US2733	19910422
	W: AU, BG, BR, CA, FI, HU, JP, KR, LK, NO, PL, RO, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT,				
	LU, ML, MR, NL, SE, SN, TD, TG				
	AU 9178591	A1	19911210	AU 1991-78591	19910422
	AU 653724	B2	19941013		
	EP 527879	A1	19930224	EP 1991-909382	19910422
	EP 527879	B1	19970205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	HU 62804	A2	19930628	HU 1992-3522	19910422
	BR 9106438	A	19930629	BR 1991-6438	19910422
	JP 05505618	T2	19930819	JP 1991-508991	19910422
	JP 07029938	B4	19950405		
	AT 148632	E	19970215	AT 1991-909382	19910422
	ES 2097208	T3	19970401	ES 1991-909382	19910422
	CA 2081564	C	19980203	CA 1991-2081564	19910422
	RU 2147875	C1	20000427	RU 1992-16534	19910422
	IL 98055	A1	19961031	IL 1991-98055	19910503
	CN 1056426	A	19911127	CN 1991-103177	19910510
	CN 1065140	B	20010502		
	ZA 9103539	A	19921230	ZA 1991-3539	19910510
	IN 177189	A	19961130	IN 1991-DE420	19910515
	SK 282181	B6	20011106	SK 1991-1515	19910522
	NO 9204321	A	19930108	NO 1992-4321	19921110
	KR 9705839	B1	19970421	KR 1992-72805	19921110
	JP 07048280	A2	19950221	JP 1994-144998	19940627
	JP 2635291	B2	19970730		
	US 5821232	A	19981013	US 1995-461914	19950605
	US 5663188	A	19970902	US 1995-468505	19950606
	CN 1307901	A	20010815	CN 2000-108186	20000429
PRAI	US 1990-522360	A2	19900511		
	WO 1991-US2733	A	19910422		
	US 1992-938126	B3	19921026		

L16 ANSWER 124 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1992:174770 CAPLUS

DN 116:174770

TI Preparation of disulfide derivatives of mercaptoacylamino acids as

cardiovascular agents
 IN Haslanger, Martin F.; Neustadt, Bernard R.; Smith, Elizabeth M.
 PA Schering Corp., USA
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9117980	A1	19911128	WO 1991-US3251	19910515
	W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, RO, SD, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	AU 9179572	A1	19911210	AU 1991-79572	19910515
	ZA 9103685	A	19920226	ZA 1991-3685	19910515
	EP 528997	A1	19930303	EP 1991-911546	19910515
	EP 528997	B1	19950201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05502038	T2	19930415	JP 1991-510190	19910515
	JP 06102648	B4	19941214		
	ES 2069893	T3	19950516	ES 1991-911546	19910515
PRAI	US 1990-525370		19900517		
	WO 1991-US3251		19910515		
OS	MARPAT 116:174770				

L16 ANSWER 125 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1991:406182 CAPLUS
 DN 115:6182
 TI Regulation of myocardial isomyosin VI in uremic rats
 AU Rambausek, M.; Kollmar, S.; Klug, D.; Mehls, O.; Ritz, E.
 CS Dep. Intern. Med. Paediatr., Ruperto Carola Univ., Heidelberg, D-6900, Germany
 SO European Journal of Clinical Investigation (1991), 21(1), 64-71
 CODEN: EJCIB8; ISSN: 0014-2972
 DT Journal
 LA English

L16 ANSWER 126 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1991:199681 CAPLUS
 DN 114:199681
 TI Treatment of **heart failure** with a quinolone derivative combined with an angiotensin-converting enzyme inhibitor
 IN O'Connor, Patrick Coleman; Defesche, Charles Leon Marie
 PA Boots Co. PLC, UK
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9010445	A1	19900920	WO 1990-EP430	19900312
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	AU 9052616	A1	19901009	AU 1990-52616	19900312
	AU 640128	B2	19930819		
	JP 04503806	T2	19920709	JP 1990-504547	19900312
	EP 527720	A1	19930224	EP 1990-904349	19900312
	EP 527720	B1	19940817		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				

ES 2057542	T3	19941016	ES 1990-904349	19900312
ZA 9001945	A	19910130	ZA 1990-1945	19900314
IL 93744	A1	19950629	IL 1990-93744	19900314
PRAI US 1989-324213		19890315		
WO 1990-EP430		19900312		
OS MARPAT 114:199681				

L16 ANSWER 127 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1990:151108 CAPLUS
 DN 112:151108

TI **Ramipril.** A review of its pharmacological properties and
 therapeutic efficacy in cardiovascular disorders
 AU Todd, Peter A.; Benfield, Paul
 CS ADIS Drug Inf. Serv., ADIS Press Ltd., Auckland, N. Z.
 SO Drugs (1990), 39(1), 110-35
 CODEN: DRUGAY; ISSN: 0012-6667
 DT Journal; General Review
 LA English

L16 ANSWER 128 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1989:491242 CAPLUS
 DN 111:91242

TI Atrial natriuretic peptide levels in congestive **heart failure**
 in man before and during converting enzyme inhibition
 AU Crozier, Ian G.; Nicholls, M. Gary; Ikram, Hamid; Espiner, Eric A.;
 Yandle, Tim G.
 CS Dep. Cardiol., Princess Margaret Hosp., Christchurch, N. Z.
 SO Clinical and Experimental Pharmacology and Physiology (1989), 16(5),
 417-24
 CODEN: CEXPB9; ISSN: 0305-1870
 DT Journal
 LA English

L16 ANSWER 129 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1988:542325 CAPLUS
 DN 109:142325

TI Effect of converting enzyme inhibitors on cardiac changes in experimental
 uremia
 AU Rambausek, Michael; Mall, Gerhard; Kollmar, Sylvia; Ritz, Eberhard
 CS Dep. Intern. Med., Univ. Heidelberg, Heidelberg, D-6900, Fed. Rep. Ger.
 SO Kidney International, Supplement (1988), 25, S201-S203
 CODEN: KISUDF; ISSN: 0098-6577
 DT Journal
 LA English

L16 ANSWER 130 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1987:508595 CAPLUS
 DN 107:108595

TI **Ramipril:** review of pharmacology
 AU Becker, Reinhard H. A.; Schoelkens, Bernard
 CS Dep. Pharmacol., Hoechst A.-G., Frankfurt/Main, D-6230/80, Fed. Rep. Ger.
 SO American Journal of Cardiology (1987), 59(10), 3D-11D
 CODEN: AJCDAG; ISSN: 0002-9149
 DT Journal; General Review
 LA English

L16 ANSWER 131 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1987:489513 CAPLUS
 DN 107:89513

TI Effect of converting enzyme inhibitors on tissue converting enzyme and
 angiotensin II: therapeutic implications
 AU Unger, Thomas; Ganten, Detlev; Lang, Rudolf E.

CS German Inst. High Blood Pressure Rés., Univ. Heidelberg, Heidelberg, 6900,
Fed. Rep. Ger.
SO American Journal of Cardiology (1987), 59(10), 18D-22D
CODEN: AJCDAG; ISSN: 0002-9149
DT Journal; General Review
LA English

L16 ANSWER 132 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:488958 CAPLUS
DN 107:88958
TI Clinical pharmacology of **ramipril**
AU Ball, Stephen G.; Robertson, J. Ian S.
CS MRC Blood Pressure Unit, West. Inform., Glasgow, G11 6NT, UK
SO American Journal of Cardiology (1987), 59(10), 23D-27D
CODEN: AJCDAG; ISSN: 0002-9149
DT Journal; General Review
LA English

L16 ANSWER 133 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1986:564742 CAPLUS
DN 105:164742
TI Cardiovascular effects of the converting enzyme inhibitor **ramipril**
(HOE 498) in anesthetized dogs with acute ischemic left ventricular
failure
AU Schoelkens, B. A.; Martorana, P. A.; Goebel, H.; Gehring, D.
CS Hoechst A.-G., Frankfurt/Main, Fed. Rep. Ger.
SO Clinical and Experimental Hypertension, Part A: Theory and Practice
(1986), A8(6), 1033-48
CODEN: CEHADM; ISSN: 0730-0077
DT Journal
LA English

=> d his

(FILE 'HOME' ENTERED AT 11:42:30 ON 16 SEP 2003)

FILE 'REGISTRY' ENTERED AT 11:42:39 ON 16 SEP 2003

L1 1 S EPLERENONE

FILE 'CAPLUS' ENTERED AT 11:43:07 ON 16 SEP 2003

E HEART
L2 277174 S E3
L3 85 S L1
L4 53 S L2 AND L3
E FAILURE
L5 148245 S E3
L6 41 S L4 AND L5
E CAPTOPRIL
L7 6439 S E3
L8 5 S L6 AND L7
L9 6434 S L7 NOT L8
L10 36 S L6 NOT L8
E E RAMIPRIL
E RAMIPRIL
L11 852 S E3
L12 1438 S L7 AND L2
L13 435 S L12 AND L5
E HYPERTENSION
L14 62537 S E3
L15 338 S L11 AND L2
L16 133 S L15 AND L5

=> s 13 and 114
L17 33 L3 AND L14

=> d 117 20-33

L17 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:161838 CAPLUS
DN 137:15532
TI Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading
AU Martinez, Diego V.; Rocha, Ricardo; Matsumura, Mamiko; Oestreicher, Eveline; Ochoa-Maya, Margarita; Roubsanthisuk, Weranuj; Williams, Gordon H.; Adler, Gail K.
CS Endocrinology-Hypertension Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
SO Hypertension (2002), 39(2, Pt. 2), 614-618
CODEN: HPRTDN; ISSN: 0194-911X
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:107160 CAPLUS
DN 136:161366
TI Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure and other cardiovascular disorders
IN Schuh, Joseph R.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 231 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002009761	A2	20020207	WO 2001-US23677	20010727
	WO 2002009761	A3	20030103		
	WO 2002009761	C2	20030710		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002042405	A1	20020411	US 2001-917425	20010727
	EP 1303305	A2	20030423	EP 2001-956001	20010727
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2003055027	A1	20030320	US 2002-126134	20020419
PRAI	US 2000-221359P	P	20000727		
	US 2001-917425	B1	20010727		
	WO 2001-US23677	W	20010727		

L17 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:107159 CAPLUS

DN 136:172753
TI Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist
combination therapy for treatment of congestive heart failure
IN Alexander, John C.; Schuh, Joseph R.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 190 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002009760	A2	20020207	WO 2001-US23670	20010727
	WO 2002009760	A3	20030123		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002123485	A1	20020905	US 2001-917403	20010727
	EP 1303306	A2	20030423	EP 2001-957290	20010727
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-221365P	P	20000727		
	WO 2001-US23670	W	20010727		

L17 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:41643 CAPLUS

DN 136:210676

TI Eplerenone: A selective aldosterone receptor antagonist (SARA)

AU Delyani, John A.; Rocha, Ricardo; Cook, Chyung S.; Tolbert, Dwain S.; Levin, Stuart; Roniker, Barbara; Workman, Diane L.; Sing, Yuen-lung L.; Whelihan, Brian

CS Skokie, IL, 60077, USA

SO Cardiovascular Drug Reviews (2001), 19(3), 185-200

CODEN: CDREEA; ISSN: 0897-5957

PB Neva Press

DT Journal; General Review

LA English

RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:923600 CAPLUS

DN 136:31688

TI Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects

IN Williams, Gordon H.; Funder, John W.; Garthwaite, Susan M.; Roniker, Barbara; Fedde, Kenton N.; Rocha, Ricardo

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 318 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001095893	A1	20011220	WO 2000-US31263	20001114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003125312 A1 20030703 US 2001-915784 20010726

PRAI US 2000-211064P P 20000613
 US 2000-211250P P 20000613
 US 2000-211253P P 20000613
 US 2000-211264P P 20000613
 US 2000-211311P P 20000613
 US 2000-211340P P 20000613
 US 2000-211451P P 20000613
 US 2000-211459P P 20000613
 US 2000-221358P P 20000727
 US 2000-221364P P 20000727
 US 2000-233056P P 20000914
 US 2001-261352P P 20010112
 US 2001-261497P P 20010112

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:923599 CAPLUS

DN 136:31687

TI Use of an aldosterone antagonist, specifically a spiro lactone-type
 steroidal compound, for the treatment or prophylaxis of
 aldosterone-mediated pathogenic effects

IN Williams, Gordon H.; Funder, John W.; Garthwaite, Susan M.; Roniker,
 Barbara; Fedde, Kenton N.; Rocha, Ricardo

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 329 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001095892	A1	20011220	WO 2000-US31155	20001114
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1289507	A1	20030312	EP 2000-978588	20001114
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	US 2003125312	A1	20030703	US 2001-915784	20010726
PRAI	US 2000-211064P	P	20000613		
	US 2000-211250P	P	20000613		
	US 2000-211253P	P	20000613		
	US 2000-211264P	P	20000613		
	US 2000-211311P	P	20000613		
	US 2000-211340P	P	20000613		

US 2000-211451P P 20000613
US 2000-211459P P 20000613
US 2000-221358P P 20000727
US 2000-221364P P 20000727
US 2000-233056P P 20000914
WO 2000-US31155 W 20001114
US 2001-261352P P 20010112
US 2001-261497P P 20010112

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:369262 CAPLUS
DN 135:235708
TI Eplerenone (GD Searle & Co)
AU Martin, Jennifer; Krum, Henry
CS Alfred Hospital, Monash University, Victoria, 3181, Australia
SO Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2001), 2(4),
521-524
CODEN: COIDAZ
PB PharmaPress Ltd.
DT Journal; General Review
LA English

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:262624 CAPLUS
DN 135:70465
TI Recent studies with eplerenone, a novel selective aldosterone receptor
antagonist
AU McMahon, Ellen G.
CS Pharmacia Corporation, St Louis, MO, 63167, USA
SO Current Opinion in Pharmacology (2001), 1(2), 190-196
CODEN: COPUBK; ISSN: 1471-4892
PB Elsevier Science Ltd.
DT Journal; General Review
LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:182738 CAPLUS
DN 135:630
TI Aldosterone receptor antagonism normalizes vascular function in
liquorice-induced **hypertension**
AU Quaschnig, Thomas; Ruschitzka, Frank; Shaw, Sidney; Luscher, Thomas F.
CS Institute of Physiology, Cardiovascular Research, University of Zurich,
Zurich, Switz.
SO Hypertension (2001), 37(2, Pt. 2), 801-805
CODEN: HPRTDN; ISSN: 0194-911X
PB Lippincott Williams & Wilkins
DT Journal
LA English

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:74077 CAPLUS
DN 134:126077
TI Pathophysiology of aldosterone and its antagonists
AU Struthers, A. D.

CS Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital
and Medical School, DD1 9SY, Dundee, UK
SO Fundamental & Clinical Pharmacology (2000), 14(6), 549-552
CODEN: FCPHEZ; ISSN: 0767-3981
PB Editions Scientifiques et Medicales Elsevier
DT Journal; General Review
LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:259979 CAPLUS

DN 132:288794

TI Sympathetic nervous system activity-reducing agents for treatment of
disease- or age-related weight loss and for enhancement of exercise
performance

IN Anker, Stefan Dietmar; Coats, Andrew Justin Stewart

PA Imperial College Innovations Limited, UK

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021509	A2	20000420	WO 1999-GB3302	19991015
	WO 2000021509	A3	20001109		
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1121111	A2	20010808	EP 1999-947762	19991015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002527378	T2	20020827	JP 2000-575485	19991015
PRAI	GB 1998-22458	A	19981015		
	GB 1998-22459	A	19981015		
	GB 1999-17181	A	19990723		
	WO 1999-GB3302	W	19991015		

L17 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:168547 CAPLUS

DN 126:152803

TI Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist
combination therapy for treatment of cardiovascular disorders, including
congestive heart failure

IN Alexander, John C.; Schuh, Joseph R.; Gorczynski, Richard J.

PA G.D. Searle & Co., USA; Alexander, John C.; Schuh, Joseph R.; Gorczynski,
Richard J.

SO PCT Int. Appl., 218 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640257	A1	19961219	WO 1996-US9335	19960605
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				

CA 2224079	AA	19961219	CA 1996-2224079	19960605
AU 9661577	A1	19961230	AU 1996-61577	19960605
AU 725689	B2	20001019		
EP 831910	A1	19980401	EP 1996-919170	19960605
EP 831910	B1	20011121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1192697	A	19980909	CN 1996-196155	19960605
BR 9609066	A	19990126	BR 1996-9066	19960605
JP 11507627	T2	19990706	JP 1996-501678	19960605
NZ 310730	A	20010126	NZ 1996-310730	19960605
RU 2166330	C2	20010510	RU 1998-100250	19960605
IL 122242	A1	20010724	IL 1996-122242	19960605
AT 209047	E	20011215	AT 1996-919170	19960605
ES 2167571	T3	20020516	ES 1996-919170	19960605
RO 118046	B1	20030130	RO 1997-2272	19960605
PL 185150	B1	20030331	PL 1996-324001	19960605
NO 9705741	A	19980129	NO 1997-5741	19971205
PRAI US 1995-486456	A	19950607		
WO 1996-US9335	W	19960605		
OS	MARPAT 126:152803			

L17 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:761815 CAPLUS
 DN 123:132882
 TI Use of aldosterone antagonists to inhibit myocardial fibrosis
 IN Weber, Karl T.
 PA Curators of the University of Missouri, USA
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9515166	A1	19950608	WO 1994-US13291	19941201
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5529992	A	19960625	US 1993-160236	19931202
	AU 9512106	A1	19950619	AU 1995-12106	19941201
	AU 703147	B2	19990318		
	EP 730458	A1	19960911	EP 1995-903131	19941201
	EP 730458	B1	20020320		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09508354	T2	19970826	JP 1994-515653	19941201
	JP 2916267	B2	19990705		
	AT 214607	E	20020415	AT 1995-903131	19941201
	US 6008210	A	19991228	US 1996-687395	19960802
	US 6245755	B1	20010612	US 1999-250259	19990216
PRAI	US 1993-160236	A	19931202		
	US 1992-871390	B2	19920421		
	WO 1994-US13291	W	19941201		
	US 1996-687395	A1	19960802		

L17 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1989:128777 CAPLUS
 DN 110:128777
 TI Antialdosterones: incidence and prevention of sexual side effects

AU De Gasparo, M.; Whitebread, S. E.; Preiswerk, G.; Jeunemaitre, X.; Corvol, P.; Menard, J.
CS Pharm. Div., CIBA-GEIGY Ltd., Basel, Switz.
SO Journal of Steroid Biochemistry (1989), 32(1B), 223-7
CODEN: JSTBBK; ISSN: 0022-4731
DT Journal
LA English

=> d 113 435 all

L13 ANSWER 435 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1980:103819 CAPLUS
DN 92:103819
TI **Captopril** in the treatment of clinical hypertension and cardiac **failure**
AU Atkinson, A. B.; Robertson, J. I. S.
CS MRC Blood Pressure Unit, Western Infirm., Glasgow, G11 6NT, UK
SO Lancet (1979), 2(8147), 836-9
CODEN: LANCAO; ISSN: 0023-7507
DT Journal; General Review
LA English
CC 1-0 (Pharmacodynamics)
AB A review, with 78 refs., discussing **captopril** [62571-86-2] therapeutics in clin. hypertension and **heart failure**.
ST **captopril** hypertension **heart failure** review
IT Hypertension
(**captopril** effect on)
IT **Heart**, disease or disorder
(**failure**, **captopril** effect on)
IT 62571-86-2
RL: BIOL (Biological study)
(hypertension and **heart failure** treatment with)


=> d 113 432 all

L13 ANSWER 432 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:114654 CAPLUS
DN 94:114654
TI Low-dose **captopril** in chronic **heart failure**: acute hemodynamic effects and long-term treatment
AU Sharpe, D. N.; Coxon, R. J.; Douglas, J. E.; Long, B.
CS Dep. Med., Univ. Auckland Sch. Med., Auckland, N. Z.
SO Lancet (1980), 2(8205), 1154-7
CODEN: LANCAO; ISSN: 0023-7507
DT Journal
LA English
CC 1-6 (Pharmacodynamics)
AB Following increasing doses of **captopril** (I) [62571-86-2], (1, 2.5, 6.25, 12.5, and 25 mg, orally at 2-h intervals) to patients with chronic **heart failure**, graded hemodynamic improvement (increased stroke-vol. index and reduced mean pulmonary wedge pressure) was obsd. from 1 h and was closely assocd. with redn. of blood pressure. Max. hemodynamic improvement for the group was seen at 6 and 7 h after 6.25- and 12.5- mg doses, when stroke-vol. index had risen 35% and mean pulmonary capillary wedge pressure had fallen 40% from control. I (12.5-50 mg every 8 h) was continued long term, and, after 3 mo generally led to improvements in symptoms, treadmill exercise duration, and echocardiog. indexes of left ventricular size and function. Repeat hemodynamic measurements were similar to optimum measurements obtained during the initial study.

ST **heart failure captopril** hemodynamic
 IT **Heart**, disease or disorder
 (**failure, captopril** treatment of, hemodynamic
 effects of)
 IT 62571-86-2
 RL: BIOL (Biological study)
 (chronic **heart failure** treatment with low doses of,
 hemodynamic effects of)

=> d 113 430 all

L13 ANSWER 430 OF 435 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:400475 CAPLUS
 DN 95:475
 TI Effect of the angiotensin-converting enzyme inhibitor, **captopril**
 , on development of renal hypertension in rats
 AU Fregly, Melvin J.; Lockley, Ora E.; Simpson, Charles E.
 CS Dep. Physiol., Coll. Med., Gainesville, FL, 32610, USA
 SO Pharmacology (1981), 22(5), 277-85
 CODEN: PHMGBN; ISSN: 0031-7012
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 GI



AB Female rats (230-260 g) made hypertensive by bilateral renal encapsulation with latex envelopes were divided into 3 equal groups. Two groups were administered the angiotensin-converting enzyme inhibitor **captopril** (SQ 14,225) (I) [62571-86-2] in drinking water at a concn. sufficient to yield a dose of 25 and 50 mg/kg/day, resp. The 3rd group was untreated. A 4th group served as a normotensive control group. Systolic blood pressures and body wts. were measured weekly during a 4-wk control and an 8-wk exptl. period. Both doses prevented the elevation of blood pressure to the level of the untreated hypertensive controls. Blood pressure of the group receiving the higher dose of I was within the range of that of the normotensive control group by the end of the expt. while that of the group receiving the lower dose was between the blood pressures of untreated hypotensive and normotensive controls. Renal encapsulation resulted in **failure** of the rats to grow normally. Administration of I at either dose had no addnl. effect on body wt. To test whether inhibition of the angiotensin-converting enzyme occurred at the doses of I used, angiotensin I (200 .mu.g/kg, s.c.) and bradykinin (200 .mu.g/kg, s.c.) were administered sep. and their effects on water intakes of control and I-treated groups tested. I inhibited the drinking response to angiotensin I while increasing it in response to bradykinin. The pressor response following i.v. administration of 1.25 .mu.g angiotensin I/kg to anesthetized rats was also studied. The groups treated with I had a significantly reduced response to angiotensin I compared with those of either normotensive groups. Apparently, inhibition of the angiotensin-converting enzyme occurred at both doses of I with the higher dose inducing a somewhat greater inhibition. At autopsy,

heart wt. of the group receiving the higher dose of I was significantly less than that of the untreated hypertensive group, but significantly greater than that of the normotensive group. Apparently, I at the doses used, provided significant protection against elevation of blood pressure in renal hypertensive rats.

ST **captopril** renal hypertension; angiotensin converting enzyme inhibitor hypertension

IT 62571-86-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antihypertensive activity of, in renal hypertension)

=> d 116 133 all

L16 ANSWER 133 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1986:564742 CAPLUS

DN 105:164742

TI Cardiovascular effects of the converting enzyme inhibitor **ramipril** (HOE 498) in anesthetized dogs with acute ischemic left ventricular **failure**

AU Schoelkens, B. A.; Martorana, P. A.; Goebel, H.; Gehring, D.

CS Hoechst A.-G., Frankfurt/Main, Fed. Rep. Ger.

SO Clinical and Experimental Hypertension, Part A: Theory and Practice (1986), A8(6), 1033-48

CODEN: CEHADM; ISSN: 0730-0077

DT Journal

LA English

CC 1-8 (Pharmacology)

AB **Ramipril** [87333-19-5] was administered during acute ischemic left ventricular **failure** induced by repeated injections of plastic microspheres into the left main coronary artery of pentobarbital-anesthetized dogs. Repeated embolizations produced stable left ventricular (LV) pump **failure** characterized by LV enddiastolic pressure of 22 mmHg, redns. in LV dp/dt max and cardiac output. Blood pressure and **heart** rate were not changed while total peripheral resistance increased. After a stabilization period, **ramipril** was administered in 2 doses at 30 or 100 .mu.g/kg as an i.v. bolus followed by continuous infusion of 3 or 10 .mu.g/kg/min for 150 min. **Ramipril** in the lower dose decreased LV end-diastolic pressure by 8 mmHg, mean pulmonary artery pressure by 4 mmHg, systemic blood pressure by 40 mmHg and total peripheral resistance by 1280 dyn .times. sec .times. cm-5. LV dp/dt max, **heart** rate and cardiac output remained unchanged during **ramipril** administration. More pronounced effects were obtained with the higher dose. The improvements of hemodynamics produced by **ramipril** during acute ischemic left ventricular **failure** in anesthetized dogs are best explained by a redn. in both preload and afterload.

ST **ramipril heart failure; heart failure** converting enzyme inhibitor

IT **Heart**, disease or disorder

(**failure**, treatment of, with converting enzyme inhibitor **ramipril**)

IT 87333-19-5

RL: BIOL (Biological study)

(**heart failure** treatment with)

=> d 116 128 all

L16 ANSWER 128 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1989:491242 CAPLUS
 DN 111:91242
 TI Atrial natriuretic peptide levels in congestive **heart failure** in man before and during converting enzyme inhibition
 AU Crozier, Ian G.; Nicholls, M. Gary; Ikram, Hamid; Espiner, Eric A.; Yandle, Tim G.
 CS Dep. Cardiol., Princess Margaret Hosp., Christchurch, N. Z.
 SO Clinical and Experimental Pharmacology and Physiology (1989), 16(5), 417-24
 CODEN: CEXPB9; ISSN: 0305-1870
 DT Journal
 LA English
 CC 2-10 (Mammalian Hormones)
 Section cross-reference(s): 14
 AB To det. the response of plasma atrial natriuretic peptide (ANP) to treatment with an angiotensin-converting enzyme (ACE) inhibitor in **heart failure**, patients were studied before and after the addn. of the ACE inhibitor **ramipril** to maintenance digoxin and diuretic treatment. Baseline arterial ANP levels were raised, but fell during **ramipril** treatment in parallel with changes in both hemodynamic recordings (arterial pressure, pulmonary artery diastolic pressure, and right atrial pressure) and hormone levels (angiotensin II and aldosterone). Coronary sinus ANP was greater than concomitant arterial levels, and the coronary sinus ANP secretion rate was calcd. to be in the range 15-119 pmol/min. Thus, an improvement in hemodynamic function during ACE inhibitor treatment is assocd. with a decline in elevated ANP levels, supporting the concept that atrial stretch or pressure regulates the secretion of atrial peptides in man.
 ST atriopeptin secretion **heart**; angiotensin converting enzyme **heart** atriopeptin
 IT Blood pressure
 (angiotensin-converting enzyme inhibition effect on, in **heart failure** in human)
 IT Blood plasma
 (atriopeptin of, in **heart failure** in human, angiotensin-converting enzyme inhibition effect on)
 IT **Heart**, disease or disorder
 (**failure**, atriopeptin of blood plasma in, of human, angiotensin-converting enzyme inhibition effect on)
 IT 9015-82-1, Angiotensin-converting enzyme
 RL: BIOL (Biological study)
 (inhibition of, atriopeptin of blood plasma response to, in **heart failure** in human)
 IT 52-39-1, Aldosterone 9015-94-5, Renin, biological studies 11128-99-7, Angiotensin II 85637-73-6, Atrial natriuretic peptide
 RL: BIOL (Biological study)
 (of blood plasma, in **heart failure** in human, angiotensin converting enzyme inhibition effect on)

=> d 116 127 all

L16 ANSWER 127 OF 133 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1990:151108 CAPLUS
 DN 112:151108
 TI **Ramipril**. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders
 AU Todd, Peter A.; Benfield, Paul
 CS ADIS Drug Inf. Serv., ADIS Press Ltd., Auckland, N. Z.
 SO Drugs (1990), 39(1), 110-35
 CODEN: DRUGAY; ISSN: 0012-6667
 DT Journal; General Review

LA English
 CC 1-0 (Pharmacology)
 AB A review, with 113 refs., on the pharmacol. of **ramipril** as an
 angiotensin-converting enzyme inhibitor and of the therapy of hypertension
 and congestive **heart failure** with **ramipril**.
 ST review **ramipril** pharmacol cardiovascular disorder
 IT Hypertension
 (therapy of, with **ramipril**, in humans and lab. animals)
 IT **Heart**, disease or disorder
 (**failure**, therapy of, with **ramipril**, in humans and
 lab. animals)
 IT 87333-19-5, **Ramipril**
 RL: BIOL (Biological study)
 (pharmacol. of and cardiovascular therapy with, in humans and lab.
 animals)

=> d his

(FILE 'HOME' ENTERED AT 11:42:30 ON 16 SEP 2003)

FILE 'REGISTRY' ENTERED AT 11:42:39 ON 16 SEP 2003

L1 1 S EPLERENONE

FILE 'CAPLUS' ENTERED AT 11:43:07 ON 16 SEP 2003

E HEART
 L2 277174 S E3
 L3 85 S L1
 L4 53 S L2 AND L3
 E FAILURE
 L5 148245 S E3
 L6 41 S L4 AND L5
 E CAPTOPRIL
 L7 6439 S E3
 L8 5 S L6 AND L7
 L9 6434 S L7 NOT L8
 L10 36 S L6 NOT L8
 E E RAMIPRIL
 E RAMIPRIL
 L11 852 S E3
 L12 1438 S L7 AND L2
 L13 435 S L12 AND L5
 E HYPERTENSION
 L14 62537 S E3
 L15 338 S L11 AND L2
 L16 133 S L15 AND L5
 L17 33 S L3 AND L14

1747 *514/473*
-

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE
 ENTRY

TOTAL
 SESSION

FULL ESTIMATED COST	157.02	163.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.21	-5.21

STN INTERNATIONAL LOGOFF AT 12:02:48 ON 16 SEP 2003

AN 1990:151108 CAPLUS
 DN 112:151108
 TI **Ramipril.** A review of its pharmacological properties and
 therapeutic efficacy in cardiovascular disorders
 AU Todd, Peter A.; Benfield, Paul
 CS ADIS Drug Inf. Serv., ADIS Press Ltd., Auckland, N. Z.
 SO Drugs (1990), 39(1), 110-35
 CODEN: DRUGAY; ISSN: 0012-6667
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 AB A review, with 113 refs., on the pharmacol. of **ramipril** as an
 angiotensin-converting enzyme inhibitor and of the therapy of hypertension
 and congestive **heart failure** with **ramipril**.
 ST review **ramipril** pharmacol cardiovascular disorder
 IT Hypertension
 (therapy of, with **ramipril**, in humans and lab. animals)
 IT **Heart**, disease or disorder
 (**failure**, therapy of, with **ramipril**, in humans and
 lab. animals)
 IT 87333-19-5, **Ramipril**
 RL: BIOL (Biological study)
 (pharmacol. of and cardiovascular therapy with, in humans and lab.
 animals)

=>